Compounds for the treatment of neurodegenerative diseases

By providing compounds with specific structures, the problem of difficult to effectively reduce the level of mutant proteins in polyQ-related neurodegenerative diseases in the prior art is solved, and efficient reduction of mutant proteins is achieved without affecting wild-type proteins, significantly slowing down the disease process and reducing side effects .

CN113891711BActive Publication Date: 2024-11-15FUDAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080020703.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-10-21
Filing Date
2020-03-11
Publication Date
2024-11-15
Estimated Expiration
2040-03-11

AI Technical Summary

Technical Problem

Existing treatments are difficult to effectively and specifically reduce the levels of mutated proteins in polyQ-related neurodegenerative diseases, especially without affecting the function of wild-type proteins, resulting in side effects and lack of targeting.

Method used

Provided a compound with a specific structure for the preparation of a drug for the prevention or treatment of polyQ-related neurodegenerative diseases, which can efficiently reduce the level of mutant proteins without affecting wild-type proteins through specific structural characteristics, including A The ring is a benzene ring, the B ring is a saturated or unsaturated five-membered or six-membered heterocycle, the C ring is a C6-10 aryl or a five-membered to ten-membered heteroaryl, L1 is a C1-C6 hydrocarbon chain, and R1 is O Or S, R2 is a specific substituent, etc.

Benefits of technology

This compound can significantly reduce the levels of mutant proteins in polyQ-related diseases, slow down disease progression, reduce side effects, and improve the specificity and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113891711B_ABST
    Figure CN113891711B_ABST
Patent Text Reader

Abstract

The present invention relates to a compound having a substituted bicyclic structure, and its pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug, and use thereof in the preparation of a drug for preventing or treating polyglutamine (polyQ)-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and specifically to a compound having a substituted bicyclic structure, and its pharmaceutically acceptable salts, stereoisomers, solvates, polymorphs, tautomers, isotopic compounds, metabolites or prodrugs, and use in the preparation of drugs for preventing or treating polyglutamine (polyQ)-related diseases. Background Art

[0002] Neurodegenerative disorders (ND) are diseases caused by abnormal death of central neurons, leading to dysfunction of the nervous system. Currently, there is a lack of treatments for NDs, and no fundamental treatments that can slow the progression of the disease are available. Many NDs are caused by proteins whose activity is unknown. Current methods for controlling protein levels, such as biological tools like RNAi and CRIPSR, are difficult to deliver, particularly to the nervous system.

[0003] One feasible therapeutic strategy is to control the levels of disease-affecting proteins through low molecular weight compounds (referred to as compounds). Enhancing the ubiquitination of disease proteins and targeting them to the proteasome degradation pathway through protein cleavage targeting chimera (PROTAC) technology is an emerging approach, but this approach alone relies on certain E3 ligases, which may not be present in diseased cells. In addition, the protein degradation capacity of the proteasome is limited, and the degradation efficiency of certain large disease proteins or aggregates that cause neurodegenerative diseases is low. Autophagy, as an important protein degradation pathway, is prevalent in eukaryotic cells and has strong protein degradation capabilities, but low selectivity. Some studies have increased protein degradation by enhancing autophagy, but such methods lack specificity.

[0004] PolyQ-related neurodegenerative diseases are a class of neurodegenerative diseases caused by mutant proteins and can be effectively treated by reducing the levels of mutant proteins. For example, Huntington's disease (HD), the most common of these, is a single-gene inherited disease in which a mutation in the CAG repeat region of the exon 1 exon of the gene HTT on chromosome 4 results in an expansion of the glutamine repeat region (polyQ) of the synthesized mutant protein (mHTT). mHTT is easily cleaved, aggregated, and toxic, ultimately leading to dysfunction and death of specific neurons. Current methods for controlling mHTT levels using low-molecular-weight compounds lack specificity, may cause side effects, and are non-allelically selective, unable to distinguish between mHTT and wild-type HTT protein (wtHTT), resulting in reduced levels of wtHTT, which has important biological functions.

[0005] Similarly, spinocerebellar ataxia type 3 (SCA3; also known as Machado-Joseph disease, MJD) is the most common autosomal dominant spinocerebellar ataxia worldwide and the second most common polyQ-related disorder after HD. It is caused by an increase in the number of CAG repeats in the Ataxin-3 gene (ATXN3; also known as MJD1 gene), which leads to the formation of an abnormally expanded polyQ at the C-terminus of the encoded protein ATXN3. Some studies have used siRNA and antisense oligonucleotides to target ATXN3, reducing the expression of mutant ATXN3 protein and demonstrating that reduced levels of mutant ATXN3 protein can have therapeutic effects (Wang, Neuroscience, 371, 2018, 138–154). Other studies are focusing on controlling the levels of mutant ATXN3 protein using low-molecular-weight compounds. Studies on enhancing autophagy by compounds, such as Menzies et al., Brain 2010, 133:93–104, and studies on reducing the level of mutant ATXN3 protein by regulating other targets, such as Costa MD, Brain, 2016, 139(11):2891-2908, have not addressed the issue of specificity. Summary of the Invention

[0006] In one aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating PolyQ-related neurodegenerative diseases

[0007]

[0008] in:

[0009] Ring A is a benzene ring;

[0010] Ring B is a saturated or unsaturated five-membered or six-membered heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0011] The C ring is selected from C 6-10 Aryl and five- to ten-membered heteroaryl, the aryl or heteroaryl being optionally substituted by one or more independently selected from R X1 The group substitution;

[0012] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0013] Alternatively, the C ring is absent and L 1 does not exist;

[0014] R1 =Y, where Y is O or S, or OR 7 ;

[0015] R 2 Each occurrence is independently selected from H, halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, =O, =S, =NR a1 、-OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 、-C(=S)OR a1 、-C(=S)NR a1 R b1 、-C(=S)R a1 、-P(=O)(OR a1 )OR b1 、-C(=NR a1 )NR b1 R c1 , -OCN, -SCN, -N=C=O, -NCS, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, =O, =S, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 、-S(=O)R a2 and -C(=NR a2 )NR b2 R c2 Substituents substituted;

[0016] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0017] R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl, alkenyl or alkynyl groups are optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven membered heterocyclic)2, =O, -COOH and C 1-6 Substitution of alkyl groups;

[0018] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl or aryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl) is substituted with a substituent;

[0019] R a1 、R b1 、Rc1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 、-S(=O)2OR Y1 、-S(=O)2R Y1 、-S(=O)2NR Y1 R Y2 、-S(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, =O, =S, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 Substituents substituted;

[0020] R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -OH, -SH, -NH2, =O and -COOH substituents;

[0021] n is 1 or 2;

[0022] Provided that the compound of formula (I) does not include the following structure:

[0023]

[0024] where R 3 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl); R 10 is H;

[0025] And the compound of formula (I) does not include the following structure:

[0026]

[0027] where R 4 -O(C 1-6 alkyl); R 5 is halogen; R 10 is CF3;

[0028] And the compound of formula (I) does not include the following structure:

[0029]

[0030] where R 4 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl);

[0031] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0032] And the compound of formula (I) does not include the following structure:

[0033]

[0034] where R 4 Selected from -OH, -O(C1-6 alkyl); R 5 is halogen; Ring C is a five- to ten-membered heteroaryl group, optionally substituted by one or more independently selected from R X1 substituted by a group.

[0035] In one embodiment, the neurodegenerative disease is spinocerebellar ataxia (such as types 1, 2, 3, 6, 7, 12, 17), dentate-nigral-rubral-pallidular-subthalamic atrophy, Huntington's disease, Huntington's disease-like syndrome-2 or spinal bulbar muscular atrophy, in particular Huntington's disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Effects of compounds on the levels of proteins containing glutamine repeat regions in HEK293T cells.

[0037] Figure 2 OI-RD affinity binding curves for compounds with varying concentrations of full-length HTT. The vertical dashed lines indicate the onset of the association and dissociation phases of affinity binding. The dashed curves represent the results of a global fit to the Langmuir reaction model.

[0038] Figure 3 .MST assay shows the affinity binding curves of the compounds to full-length HTT.

[0039] Figure 4 Compounds for Hdh Q140 / Q7 Effects of HTT levels on mouse cortical neurons.

[0040] Figure 5 Compound 1 for Hdh Q7 / Q7 Effects of HTT levels on mouse cortical neurons.

[0041] Figure 6 . Antibodies MW1 and 3B5H10 were used to detect the N-terminal fragment of mHTT.

[0042] Figure 7 .Hdh after compound treatment Q140 / Q7 Results of mouse cortical neuron cell viability assay.

[0043] Figure 8 Effects of compounds at 100 nM concentration on mHTT levels in primary fibroblasts from HD patients.

[0044] Figure 9 Effects of compounds on mHTT levels in immortalized fibroblasts from HD patients.

[0045] Figure 10 Compound 2 reduces mHTT levels in immortalized HD patient fibroblasts.

[0046] Figure 11 Effects of compounds on mHTT levels in neurons differentiated from HD patient-derived induced pluripotent stem cells (iPSCs).

[0047] Figure 12 Effects of compounds on apoptosis of neurons differentiated from HD patient-induced stem cells (iPSCs). The vertical axis spans 50 μM.

[0048] Figure 13 Effects of compounds on apoptosis of neurons differentiated from HD patient-induced stem cells (iPSCs).

[0049] Figure 14 Effects of compounds on mHTT levels in Huntington's disease flies.

[0050] Figure 15 Effects of compounds on survival in Huntington's disease flies.

[0051] Figure 16 Effects of compounds on the crawling ability of Huntington's disease flies.

[0052] Figure 17 Effects of intracerebroventricular injection of compounds on cortical mHTT and wtHTT levels in Huntington's disease mice.

[0053] Figure 18 Effects of intraperitoneal injection of compound 2 on the levels of mHTT and wtHTT in the cortex of Huntington's disease mice.

[0054] Figure 19 Effects of intraperitoneal injection of compound 2 on the levels of mHTT and wtHTT in the striatum of Huntington's disease mice.

[0055] Figure 20 . Detection of mHTT aggregates in the cortex of Huntington's disease mice after intraperitoneal injection of compound 2.

[0056] Figure 21 Effects of intraperitoneal injection of compound 2 on behavioral deficits in Huntington's disease mice.

[0057] Figure 22 Effects of compounds on ATXN3 protein levels in fibroblasts from patients with spinocerebellar ataxia type 3.

[0058] Figure 23 Effects of compounds on mutant ATXN1 protein levels in HEK293T cells. DETAILED DESCRIPTION

[0059] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. In the event of a conflict, the definitions provided herein shall prevail. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient. All patents, published patent applications, and publications cited herein are incorporated herein by reference.

[0060] General Terms and Definitions

[0061] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. In the event of a conflict, the definitions provided herein shall prevail. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient. All patents, published patent applications, and publications cited herein are incorporated herein by reference.

[0062] The terms "include," "comprising," "having," "containing," or "involving," and their variations herein, are inclusive or open-ended and do not exclude other unrecited elements or method steps. Those skilled in the art will understand that the above terms, such as "comprising," encompass the meaning of "consisting of."

[0063] The term "one or more" or the similar expression "at least one" may mean, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.

[0064] When the lower and upper limits of a numerical range are disclosed, any value and any included range falling within the range are specifically disclosed. In particular, each range of values ​​disclosed herein should be understood to mean each value and range encompassed within the broader range. For example, the expression "ATXN1 with a polyQ length ≥ 40" can encompass situations where the polyQ length is ≥ 41. For example, "ATXN2 with a polyQ length ≥ 33" can encompass situations where the polyQ length is ≥ 34. For example, "ATXN3 with a polyQ length ≥ 41" can encompass situations where the polyQ length is ≥ 62, and can encompass, for example, situations where the polyQ length is 74. For example, "ATXN3 with a polyQ length < 41" can encompass situations where the polyQ length is 27. For example, "ATXN7 with a polyQ length ≥ 19" can encompass situations where the polyQ length is ≥ 38. For example, "TBP with a polyQ length ≥ 44" can encompass situations where the polyQ length is ≥ 45. For example, "ATN1 with a polyQ length ≥ 39" can encompass situations where the polyQ length is ≥ 49. For example, "HTT with polyQ length ≥ 36" may include polyQ lengths of 47, 49, 55, 68, 72, 73, 111, 128, or 140, etc. For another example, "HTT with polyQ length < 36" may include polyQ lengths of 7, 16, 19, 23, or 25, etc. For example, "AR with polyQ length ≥ 37" may include polyQ lengths of ≥ 38.

[0065] The expression mn used herein refers to the range from m to n and the subranges and individual point values ​​therein. For example, the expression "C1-C8" or "C 1-8 " covers the range of 1-8 carbon atoms and should be understood to also cover any subranges and each point value therein, such as C2-C5, C3-C4, C1-C2, C1-C3, C1-C4, C1-C5, C1-C6, C1-C7, etc., as well as C1, C2, C3, C4, C5, C6, C7, C8, etc. For example, the expression "C3-C 10 ” or “C 3-10 " should also be understood in a similar manner, for example, any sub-ranges and point values ​​contained therein may be encompassed, such as C3-C9, C6-C9, C6-C8, C6-C7, C7-C 10 , C7-C9, C7-C8, C8-C9, etc. and C3, C4, C5, C6, C7, C8, C9, C 10Etc. For another example, the expression "three to ten yuan" should be understood to include any sub-ranges therein and each point value, such as three to five yuan, three to six yuan, three to seven yuan, three to eight yuan, four to five yuan, four to six yuan, four to seven yuan, four to eight yuan, five to seven yuan, five to eight yuan, six to seven yuan, six to eight yuan, nine to ten yuan, etc., as well as three, four, five, six, seven, eight, nine, ten yuan, etc. Other similar expressions herein should also be understood in a similar manner.

[0066] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes both occurring and not occurring.

[0067] The terms "substituted" and "substituted" refer to the replacement of one or more (e.g., one, two, three, or four) hydrogen atoms on the designated atom with a selected group selected from the indicated group, provided that the normal atomic valence of the designated atom in the current situation is not exceeded and the substitution results in a stable compound. Combinations of substituents and / or variables are permissible only if such combinations result in stable compounds. When a substituent is described as absent, it is understood that the substituent may be replaced by one or more hydrogen atoms, provided that the structure results in a stable compound.

[0068] If a substituent is described as "optionally substituted," the substituent may be unsubstituted or substituted. If an atom or group is described as optionally substituted with one or more of the substituents listed, one or more hydrogen atoms on the atom or group may be replaced by independently selected, optional substituents. When the substituent is oxo (i.e., =0), it means that two hydrogen atoms are replaced.

[0069] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent. When a bond to a substituent is shown to pass through a bond connecting two atoms in a ring, then such a substituent may be bonded to any ring atom in the substitutable ring.

[0070] When any variable (such as R), and variables with a tag (such as R X1 、R X2 、R 7 、R 8 、R a1 、R b1 、R c1 、R a2 、R b2 、R c2When a group (e.g., ) occurs more than once in a compound's composition or structure, its definition is independent at each occurrence. For example, if a group is substituted with 0, 1, 2, 3, or 4 R substituents, the group may be optionally substituted with up to four R substituents, and the options for each R substituent at each occurrence are independent of each other.

[0071] The term "halo" or "halogen" or "halo" is understood to mean a fluorine (F), chlorine (Cl), bromine (Br) or iodine (I) atom, preferably a fluorine, chlorine or bromine atom.

[0072] The term "alkyl" refers to a straight or branched chain saturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms, which is connected to the rest of the molecule by a single bond. "Alkyl" can have 1 to 8 carbon atoms, i.e., "C1-C8 alkyl", for example, C 1-4 Alkyl, C 1-3 Alkyl, C 1-2 Alkyl, C3 alkyl, C4 alkyl, C 1-6 Alkyl, C 3-6 Alkyl. Non-limiting examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl, or 1,2-dimethylbutyl, or isomers thereof.

[0073] The term "alkylene", when used herein alone or in combination with other groups, refers to a straight or branched chain saturated divalent hydrocarbon group. For example, the term "C 1-6 The term "alkylene" refers to an alkylene group having 1 to 6 carbon atoms, for example, methylene, ethylene, propylene, butylene, pentylene, hexylene, 1-methylethylene, 2-methylethylene, methylpropylene or ethylpropylene, etc.

[0074] The term "alkenyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one double bond. 2-8 Alkenyl", such as C 2-4 Alkenyl, C 3-4Alkenyl. Non-limiting examples of alkenyl groups include, but are not limited to, vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, (E)-but-2-enyl, (Z)-but-2-enyl, (E)-but-1-enyl, (Z)-but-1-enyl, and the like.

[0075] The term "alkynyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one triple bond. 2-8 Alkynyl", such as C 2-4 Alkynyl, C 3-4 Alkynyl. Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, and the like.

[0076] The term "cycloalkyl" refers to a saturated or unsaturated non-aromatic cyclic hydrocarbon group composed of carbon atoms and hydrogen atoms, preferably containing 1 or 2 rings. The cycloalkyl group can be a monocyclic, fused polycyclic, bridged or spirocyclic structure. The cycloalkyl group can have 3 to 10 carbon atoms, i.e., "C 3-10 Cycloalkyl", such as C 3-8 Cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, C7 cycloalkyl. Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.1]heptyl, and spiro[3.3]heptyl. The term also encompasses situations where a C atom may be substituted with oxo (=O).

[0077] The term "heterocyclyl" or "heterocycloalkyl" refers to a monocyclic or bicyclic ring system (three- to ten-membered, three- to eight-membered, three- to seven-membered, four- to six-membered) having, for example, 3-10 ring atoms (suitably 3-8, more suitably 3-7, and especially 4-6), wherein at least one ring atom (e.g., 1, 2, or 3) is a heteroatom selected from N, O, and S, and the remaining ring atoms are C. The ring system may be saturated (also understood as the corresponding "heterocycloalkyl") or unsaturated (i.e., having one or more double and / or triple bonds within the ring). "Heterocyclyl" or "heterocycloalkyl" is not aromatic. The term also encompasses cases where a C atom may be substituted by oxo (=O) and / or a ring S atom may be substituted by one or two oxo (=O).

[0078] The heterocyclic group can be, for example, a four-membered ring, such as azetidinyl, oxetanyl; or a five-membered ring, such as tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, oxopyrrolidinyl, 2-oxoimidazolidin-1-yl; or a six-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, 1,1-dioxo-1,2-thiazin-2-yl or trithianyl; or a seven-membered ring, such as diazepine, Optionally, the heterocyclic group may be benzo-fused.

[0079] The heterocyclic group may be bicyclic, without limitation, for example, a five-membered and a five-membered ring, such as a hexahydrocyclopenta[c]pyrrol-2(1H)-yl) ring; or a five-membered and a six-membered bicyclic ring, such as a hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl ring.

[0080] As mentioned above, the heterocycle may be unsaturated, i.e., it may contain one or more double bonds, without being limited thereto. For example, an unsaturated heterocycle containing a nitrogen atom may be a 1,6-dihydropyrimidine, 1,2-dihydropyrimidine, 1,4-dihydropyrimidine, 1,6-dihydropyridine, 1,2-dihydropyridine, 1,4-dihydropyridine, 2,3-dihydro-1H-pyrrole, 3,4-dihydro-1H-pyrrole, 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl, or 4H-[1,4]thiazinyl ring, an unsaturated heterocycle containing an oxygen atom may be a 2H-pyran, 4H-pyran, or 2,3-dihydrofuran, and an unsaturated heterocycle containing a sulfur atom may be a 2H-thiopyran or 4H-thiopyran. The heterocycle may be benzo-fused, without being limited thereto, for example, a dihydroisoquinolinyl ring.

[0081] The term "aryl" refers to an all-carbon monocyclic or fused polycyclic (e.g., bicyclic) aromatic ring group having a conjugated π electron system. For example, an aryl group may have 6-14 carbon atoms, preferably 6-10 carbon atoms, and more preferably 6 or 10 carbon atoms. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and anthracenyl.

[0082] The term "heteroaryl" is to be understood as preferably meaning a monovalent monocyclic, bicyclic or tricyclic aromatic ring system having 5, 6, 7, 8, 9 or 10 ring atoms ("five-membered to ten-membered heteroaryl"), in particular 5 or 6 or 9 or 10 ring atoms, and containing at least one (suitably 1 to 4, more suitably 1, 2 or 3) heteroatom(s) which may be identical or different, such as oxygen, nitrogen or sulfur. Furthermore, in each case the heteroaryl group may be benzofused. In particular, the heteroaryl group is selected from thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl and the like, and benzo derivatives thereof, such as benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl and the like; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like, and benzo derivatives thereof, such as quinolyl, quinazolinyl, isoquinolyl and the like; or azocinyl, indolizinyl, purinyl and the like, and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, carbazolyl, acridinyl and the like.

[0083] The term "C1-C6 hydrocarbon chain" refers to a chain group consisting of carbon atoms and hydrogen atoms, which may be linear or branched and contain 1 to 8 (particularly 1 to 5, such as 1, 2, 3, 4 or 5) carbon atoms. The hydrocarbon chain may be saturated (i.e., a C1-C6 alkylene group) or unsaturated, i.e., may contain one or more (preferably one) carbon-carbon double or triple bonds.

[0084] An alkylene group may have 1 to 8 carbon atoms, i.e., a "C 1-6 Alkylene", such as C 1-5 Alkylene, C 1-4 Alkylene, C1-3 alkylene, C 1-2 Alkylene, C3 alkylene, and C1 alkylene, i.e., methylene. Non-limiting examples of alkylene include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2-), 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), and the like.

[0085] The term "neurodegenerative disease" refers to diseases caused by the loss or impairment of neurons and / or their myelin sheaths. Characteristic pathological structures, such as insoluble protein aggregates, can be observed within the brain neurons of patients with neurodegenerative diseases. These aggregates can be cytotoxic, leading to neuronal loss and disease progression.

[0086] The term "polyQ" or "polyglutamine" refers to the glutamine repeat region in the protein. Glutamine is encoded by the cytosine-adenine-guanine (CAG) in the gene, and the length of the glutamine repeat region is related to the number of CAG repeats in the gene exons. Therefore, an increase in the number of CAG repeats in the gene exons will cause the synthesized protein glutamine repeat region to expand. Known polyQ abnormal expansion proteins are associated with some neurodegenerative diseases. As used herein, the gene name can be represented by the form of "Q+number" to represent the number of CAG repeats in the exon, such as Q25 or Q72, representing 25 or 72 repeats of CAG in the exon, respectively. The protein name can be represented by the form of "Q+number" as above to represent the length of the glutamine repeat region, such as Q27 or Q73, representing that the length of the glutamine repeat region is 27 Q (glutamine) or 73 Q, respectively. The CAG repeats or glutamine repeats indicated by the form of "Q+number" herein are all continuous repeats. Unless otherwise specified, the polyQ length in this article refers to the length of the continuously repeated glutamine region.

[0087] The term "polyQ-associated neurodegenerative disease" refers to neurodegenerative diseases associated with abnormal polyQ expansion or neurodegenerative diseases that respond to the levels of proteins containing expanded polyQ. It is a group of clinically and genetically heterogeneous neurodegenerative diseases. "Normal polyQ" refers to proteins with less than a specific number of polyQ lengths under normal physiological conditions. Correspondingly, "abnormal polyQ expansion" refers to proteins with polyQ lengths greater than normal. In disease or pathological conditions, polyQ lengths can be longer. By way of example, polyQ-associated neurodegenerative diseases include, but are not limited to, spinocerebellar ataxia (SCA) type 1 (polyQ length ≥ 41), type 2 (polyQ length ≥ 34), type 3 (polyQ length ≥ 62), type 7 (polyQ length ≥ 38), type 12 (polyQ length ≥ 46), and type 17 (polyQ length ≥ 45); as well as dentatorubral-pallidoluysian atrophy (DRPLA, polyQ length ≥ 49), Huntington's disease (HD, polyQ length ≥ 36), and spinal-bulbar muscular atrophy (SBMA, polyQ length ≥ 38). These diseases are caused by expansions of CAG repeat regions in the ATXN1, ATXN2, ATXN3, ATXN7, ATXN12, TBP, ATN1, HTT, and AR genes, respectively (Lesley Jones et al., DNA repair in the trinucleotide repeat disorders, Lancet Neurol. 2017;16:88–96). Among them, spinocerebellar ataxia type 3 (SCA3, also known as Machado-Joseph disease, MJD) is the most common autosomal dominant spinocerebellar ataxia worldwide and the second most common polyQ-related disorder after HD. It is caused by an increase in the number of CAG repeats in the Ataxin-3 gene (ATXN3; also known as the MJD1 gene), which leads to the formation of an abnormally expanded polyQ at the C-terminus of the encoded protein ATXN3.Examples of normal polyQ proteins described herein include, but are not limited to, ATXN1 with a polyQ length <40, ATXN2 with a polyQ length <33, ATXN3 with a polyQ length <41, ATXN7 with a polyQ length <19, ATXN12 with a polyQ length <46, TBP with a polyQ length <44, ATN1 with a polyQ length <39, HTT with a polyQ length <36, and AR with a polyQ length <37. Correspondingly, examples of abnormal polyQ expansion proteins described herein include, but are not limited to, ATXN1 with a polyQ length ≥40, ATXN2 with a polyQ length ≥33, ATXN3 with a polyQ length ≥41, ATXN7 with a polyQ length ≥19, ATXN12 with a polyQ length ≥46, TBP with a polyQ length ≥44, ATN1 with a polyQ length ≥39, HTT with a polyQ length ≥36, and AR with a polyQ length ≥37.

[0088] The term "pharmaceutically acceptable" means that it is within the scope of normal medical judgment and will not cause undue toxicity, irritation, allergic response, etc. when in contact with the patient's tissues, has a reasonable benefit-risk ratio, and can be effectively used for the intended purpose.

[0089] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof. Suitable acid addition salts are formed from acids that form pharmaceutically acceptable salts. Examples include hydrochlorides, acetates, aspartates, benzoates, bicarbonates / carbonates, glucoheptonates, gluconates, nitrates, orotates, palmitates, and other similar salts. Suitable base addition salts are formed from bases that form pharmaceutically acceptable salts. Examples include aluminum salts, arginine salts, choline salts, magnesium salts, and other similar salts. Methods for preparing pharmaceutically acceptable salts of the compounds of the present invention are known to those skilled in the art.

[0090] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All of these isomers and their mixtures are included within the scope of the present invention. In certain embodiments, preferred compounds are those isomeric compounds that exhibit superior biological activity. Purified or partially purified isomers and stereoisomers of the compounds of the present invention, or racemic mixtures or diastereomeric mixtures, are also included within the scope of the present invention. Purification and isolation of such substances can be achieved by standard techniques known in the art.

[0091] Optically pure enantiomers can be obtained by resolving racemic mixtures according to conventional methods, for example, by forming diastereomeric salts with optically active acids or bases, or by forming covalent diastereomers. Mixtures of diastereomers can be separated into individual diastereomers based on their physical and / or chemical differences by methods known in the art (e.g., by chromatography or fractional crystallization). The optically active enantiomer base or acid is then released from the separated diastereomeric salts. Another method for separating racemic enantiomers can be chiral chromatography (e.g., a chiral HPLC column), and the separated chiral isomers can be subjected to conventional derivatization treatment or not prior to separation, depending on which method can achieve more efficient separation of the chiral isomers. Enzymatic methods can also be used to separate derivatized or underivatized chiral isomers. Similarly, optically pure compounds of the present invention can be obtained by chiral synthesis using optically active starting materials.

[0092] In addition, the compounds of the present invention may exist in the form of tautomers. The present invention includes all possible tautomers of the compounds of the present invention, including single tautomers or any mixtures of said tautomers in any ratio.

[0093] The compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain a polar solvent as a structural element of the crystal lattice of the compound, in particular water, methanol or ethanol. The amount of polar solvent, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.

[0094] The present invention also encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be single polymorphs or mixtures of more than one polymorph in any ratio.

[0095] The present invention also includes all pharmaceutically acceptable isotopically labeled compounds which are identical to the compounds of the present invention, except that one or more atoms are replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature.

[0096] Also included within the scope of the present invention are metabolites of the compounds of the present invention, i.e., substances formed in vivo upon administration of the compounds of the present invention. Metabolites of compounds can be identified using techniques known in the art, and their activity can be characterized using assays. Such products can be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, etc. of the administered compound. Thus, the present invention includes metabolites of the compounds of the present invention, including compounds produced by methods that contact a compound of the present invention with a mammal for a period of time sufficient to produce a metabolite thereof.

[0097] The present invention further includes within its scope a prodrug of the compound of the present invention, which is a compound of the present invention that can have less pharmacological activity or no pharmacological activity when administered to or on the body, for example, by hydrolytic cleavage and conversion into a compound of the present invention with desired activity. Typically, such a prodrug can be a functional group derivative of the compound, which is easily converted into a desired therapeutically active compound in vivo. For a review of prodrugs and their preparation methods, see, for example, J. Rautio et al., Nature Reviews Drug Discovery (2008) 7, 255-270 and Prodrugs: Challenges and Rewards (V. Stella et al. ed., Springer, 2007). The prodrug of the present invention can be prepared, for example, by replacing the appropriate functional group present in the compound of the present invention with some portion known to those skilled in the art as "front-part (pro-moiety)"

[0098] The term "polymorph" or "polymorph" refers to a single polymorph or a mixture of more than one polymorph in any proportion.

[0099] The term "crystalline form" or "crystal" refers to any solid material exhibiting a three-dimensional ordering, in contrast to amorphous solid material, which produces a characteristic X-ray powder diffraction pattern with well-defined peaks.

[0100] The term "amorphous" refers to any solid material that has no order in three dimensions.

[0101] The term "hydrate" describes a solvate comprising the drug and either stoichiometric or non-stoichiometric amounts of water.

[0102] The term "pharmaceutically acceptable carrier" refers to substances that are non-irritating to organisms and do not impair the biological activity and properties of the active compound. "Pharmaceutically acceptable carriers" include, but are not limited to, glidants, sweeteners, diluents, preservatives, dyes / colorants, flavorings, surfactants, wetting agents, dispersants, disintegrants, stabilizers, solvents, or emulsifiers. Non-limiting examples of such carriers include calcium carbonate, calcium phosphate, various sugars and starches, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycol.

[0103] The term "administration" or "administering" refers to a method that enables a compound or composition to be delivered to a desired biological site of action. These methods include, but are not limited to, oral or parenteral (including intracerebroventricular, intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular injection or infusion), topical, rectal administration, and the like. In particular, injection or oral administration.

[0104] As used herein, the term "treating" includes alleviating, alleviating or ameliorating a disease or symptom, preventing other symptoms, ameliorating or preventing the underlying metabolic factors of a symptom, inhibiting a disease or symptom, for example, preventing the disease or symptom from developing, alleviating a disease or symptom, promoting remission of a disease or symptom, or stopping the symptoms of a disease or symptom, and extends to include prevention. "Treatment" also includes achieving a therapeutic benefit and / or a prophylactic benefit. A therapeutic benefit refers to the eradication or amelioration of the condition being treated. In addition, a therapeutic benefit is achieved by eradicating or ameliorating one or more physiological signs associated with the underlying disease, and although the patient may still have the underlying disease, an improvement in the patient's disease is observed. A prophylactic benefit refers to the use of a composition by a patient to prevent the risk of a certain disease, or when a patient develops one or more physiological symptoms of a disease, even though the disease has not yet been diagnosed.

[0105] The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that is effective in treating or preventing a target disorder, disease, or condition.

[0106] With respect to a drug, pharmaceutical unit, or active ingredient, the terms "effective amount," "therapeutically effective amount," or "prophylactically effective amount" refer to a sufficient amount of the drug or pharmaceutical agent to achieve the desired effect with acceptable side effects. The determination of an effective amount varies from person to person, depending on the individual's age and general condition, as well as the specific active substance. The appropriate effective amount in each individual case can be determined by those skilled in the art through routine testing.

[0107] As used herein, "subject" includes humans and non-human animals. Exemplary human subjects include human subjects suffering from diseases (e.g., the diseases described herein) (referred to as patients) or normal individuals. "Non-human animals" herein include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).

[0108] The following detailed description of the invention is intended to illustrate non-limiting embodiments so that other technical personnel in the art can more fully understand the technical solutions, principles and practical applications of the present invention, so that other technical personnel in the art can modify and implement the present invention in many forms to best adapt it to the requirements of specific uses.

[0109] Compounds of the present invention and uses thereof

[0110] In one aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases

[0111]

[0112] in:

[0113] Ring A is a benzene ring;

[0114] Ring B is a saturated or unsaturated five-membered or six-membered heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0115] The C ring is selected from C 6-10 Aryl and five- to ten-membered heteroaryl, the aryl or heteroaryl being optionally substituted by one or more independently selected from R X1 The group substitution;

[0116] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0117] Alternatively, the C ring is absent and L 1 does not exist;

[0118] R 1 =Y, where Y is O or S, or OR 7 ;

[0119] R 2 Each occurrence is independently selected from H, halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, =O, =S, =NR a1 、-OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 、-C(=S)OR a1 、-C(=S)NR a1 R b1 、-C(=S)R a1 、-P(=O)(OR a1 )OR b1 、-C(=NR a1 )NR b1 R c1 , -OCN, -SCN, -N=C=O, -NCS, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, =O, =S, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 、-S(=O)R a2 and -C(=NR a2 )NR b2 Rc2 Substituents substituted;

[0120] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0121] R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl, alkenyl or alkynyl groups are optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven membered heterocyclic)2, =O, -COOH and C 1-6 Substitution of alkyl groups;

[0122] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl or aryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl) is substituted with a substituent;

[0123] R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 、-S(=O)2OR Y1 、-S(=O)2R Y1 、-S(=O)2NR Y1 R Y2 、-S(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, =O, =S, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 Substituents substituted;

[0124] R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -OH, -SH, -NH2, =O and -COOH substituents;

[0125] n is 1 or 2;

[0126] Provided that the compound of formula (I) does not include the following structure:

[0127]

[0128] where R 3 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl); R 10 is H;

[0129] And the compound of formula (I) does not include the following structure:

[0130]

[0131] where R 4 -O(C 1-6 alkyl); R 5 is halogen; R 10 is CF3;

[0132] And the compound of formula (I) does not include the following structure:

[0133]

[0134] where R 4 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl);

[0135] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0136] And the compound of formula (I) does not include the following structure:

[0137]

[0138] where R 4 Selected from -OH, -O(C 1-6 alkyl); R 5 is halogen; Ring C is a five- to ten-membered heteroaryl group, optionally substituted by one or more independently selected from R X1 substituted by a group.

[0139] In one embodiment, R 1 In another embodiment, R 1 =S. In another embodiment, R1 OR 7 .

[0140] In one embodiment, Ring B is a saturated or unsaturated five-membered or six-membered heterocyclic ring containing 1, 2, or 3 heteroatoms independently selected from N, O, and S. In one embodiment, Ring B is a saturated or unsaturated five-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from N and O. In another embodiment, Ring B is a dihydropyrrole. In another embodiment, Ring B is selected from 2,3-dihydro-1H-pyrrole and 3,4-dihydro-1H-pyrrole, preferably 2,3-dihydro-1H-pyrrole. In yet another embodiment, Ring B is pyrrolidine.

[0141] In a more preferred embodiment, the AB ring system is wherein Y is O or S; and the C ring is a five- to seven-membered heteroaryl group, preferably a five- to six-membered heteroaryl group, in particular a five-membered heteroaryl group, the heteroaryl group being optionally substituted by 1, 2, 3, 4 or 5 groups each independently selected from R X1 In a particular embodiment, the AB ring is and the C ring is a five- to seven-membered heteroaryl group, preferably a five- to six-membered heteroaryl group, in particular a five-membered heteroaryl group, wherein the heteroaryl group is optionally substituted by 1, 2, 3, 4 or 5 groups each independently selected from R X1 In another embodiment, the C ring contains 1, 2, 3 or 4 heteroatoms, each of which is independently selected from N, O and S, preferably selected from N and O. In yet another embodiment, the C ring contains at least one N atom. In one embodiment, the C ring is a five-membered heteroaryl group containing 1 or 2 N atoms, optionally substituted by 1, 2, 3, 4 or 5 groups, each independently selected from R X1 In another embodiment, the C ring is selected from pyrrole and imidazole.

[0142] In one embodiment, Ring B is a saturated or unsaturated six-membered heterocyclic ring containing one or two heteroatoms independently selected from N and O. In another embodiment, Ring B is a dihydropyrimidine. In a preferred embodiment, Ring B is selected from 1,6-dihydropyrimidine, 1,2-dihydropyrimidine, and 1,4-dihydropyrimidine.

[0143] In a more preferred embodiment, the AB ring system is wherein Y is O or S. In a particular embodiment, the AB ring is

[0144] In another embodiment, the B ring is 2H-pyran or 4H-pyran. In a preferred embodiment, the AB ring is wherein Y is O or S. In a particular embodiment, the AB ring is

[0145] In another embodiment, ring C is phenyl, optionally substituted by 1, 2, 3, 4 or 5 groups each independently selected from R X1 substituted by a group.

[0146] In one embodiment, L 1 In another embodiment, L 1 is a C1-C6 hydrocarbon chain. In a preferred embodiment, L 1 It is a C1-C2 hydrocarbon chain.

[0147] In one embodiment, the AB ring system is The C ring is absent and L 1 Does not exist.

[0148] In another embodiment:

[0149] Ring A is a benzene ring;

[0150] Ring B is a saturated or unsaturated five-membered or six-membered heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0151] The C ring is selected from C 6-10 Aryl and five- to ten-membered heteroaryl, the aryl or heteroaryl being optionally substituted by one or more independently selected from R X1 The group substitution;

[0152] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0153] R 1 =Y, where Y is O or S, or OR 7 ;

[0154] R 2 Each occurrence is independently selected from H, halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, =O, =S, =NR a1 、-OR a1 、-SR a1 、-NR a1 Rb1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 、-C(=S)OR a1 、-C(=S)NR a1 R b1 、-C(=S)R a1 、-P(=O)(OR a1 )OR b1 、-C(=NR a1 )NR b1 R c1 , -OCN, -SCN, -N=C=O, -NCS, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, =O, =S, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 、-S(=O)R a2 and -C(=NR a2 )NR b2 R c2 Substituents substituted;

[0155] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0156] R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl, alkenyl or alkynyl groups are optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven membered heterocyclic)2, =O, -COOH and C 1-6 Substitution of alkyl groups;

[0157] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl or aryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl) is substituted with a substituent;

[0158] R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NRY1 R Y2 、-C(=O)R Y1 、-S(=O)2OR Y1 、-S(=O)2R Y1 、-S(=O)2NR Y1 R Y2 、-S(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, =O, =S, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 Substituents substituted;

[0159] R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -OH, -SH, -NH2, =O and -COOH substituents;

[0160] n is 1;

[0161] Provided that the compound of formula (I) does not include the following structure:

[0162]

[0163] where R 4 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl);

[0164] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0165] And the compound of formula (I) does not include the following structure:

[0166]

[0167] where R 4 Selected from -OH, -O(C 1-6 alkyl); R 5 is halogen; Ring C is a five- to ten-membered heteroaryl group, optionally substituted by one or more independently selected from R X1 substituted by a group.

[0168] The structure described by the following formula (II) falls within the scope of the structure described by formula (I). In another aspect of the present invention, there is provided a compound of formula (II), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases.

[0169]

[0170] in:

[0171] Y is O or S;

[0172] Ring C is a five- to seven-membered heteroaryl group, wherein the heteroaryl group is optionally substituted by one or more independently selected from R X1 The group substitution;

[0173] R 2 Selected from H, C 1-8 alkyl;

[0174] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0175] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0176] where R X1 、R X2 As defined in formula (I).

[0177] In one embodiment, Y is O. When Y is O, formula (II) is

[0178] In one embodiment, the C ring is a five- to six-membered heteroaryl group, which is optionally substituted by 1, 2, 3, 4 or 5 groups each independently selected from R X1 In a preferred embodiment, the C ring is a five-membered heteroaryl group, which is optionally substituted by 1, 2, 3, 4 or 5 groups each independently selected from R X1 In another embodiment, the C ring contains 1, 2, 3 or 4 heteroatoms, each of which is independently selected from N, O and S, preferably selected from N and O. In yet another embodiment, the C ring contains at least one N atom. In one embodiment, the C ring is a five-membered heteroaryl group containing 1 or 2 N atoms, optionally substituted by 1, 2, 3, 4 or 5 groups, each independently selected from R X1 In another embodiment, the C ring is selected from pyrrole and imidazole.

[0179] In one embodiment, L 1 In another embodiment, L 1 is a C1-C6 hydrocarbon chain. In a preferred embodiment, L 1 is a C1-C2 hydrocarbon chain. 1 In a particular embodiment, L 1 In another particular embodiment, L 1 for

[0180] In another particular embodiment, the compound of formula (II) is selected from:

[0181]

[0182] The structure described by the following formula (III) falls within the scope of the structure described by formula (I). In another aspect of the present invention, there is provided a compound of formula (III), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases.

[0183]

[0184] in:

[0185] Ring B is a saturated or unsaturated six-membered heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0186] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0187] Alternatively, the C ring is absent and L 1 does not exist;

[0188] A ring, L 1 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R X1 , n is as defined in formula (I);

[0189] Provided that the compound of formula (III) does not include the following structure:

[0190]

[0191] where R 3 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl); R 10 is H;

[0192] And the compound of formula (III) does not include the following structure:

[0193]

[0194] where R 4 -O(C 1-6 alkyl); R 5 is halogen; R 10 is CF3;

[0195] And the compound of formula (III) does not include the following structure:

[0196]

[0197] where R 4 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl);

[0198] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0199] And the compound of formula (III) does not include the following structure:

[0200]

[0201] where R 4 Selected from -OH, -O(C 1-6alkyl); R 5 is halogen; Ring C is a five- to ten-membered heteroaryl group, optionally substituted by one or more independently selected from R X1 substituted by a group.

[0202] In one embodiment, Ring B is a saturated or unsaturated six-membered heterocyclic ring containing 1, 2, or 3 heteroatoms independently selected from N, O, and S. In one embodiment, Ring B is a saturated or unsaturated six-membered heterocyclic ring containing 1 or 2 heteroatoms independently selected from N and O. In another embodiment, Ring B is a dihydropyrimidine. In a preferred embodiment, Ring B is selected from 1,6-dihydropyrimidine, 1,2-dihydropyrimidine, and 1,4-dihydropyrimidine.

[0203] In a more preferred embodiment, the AB ring system is wherein Y is O or S. In a particular embodiment, the AB ring is

[0204] In another embodiment, the B ring is 2H-pyran or 4H-pyran. In a preferred embodiment, the AB ring is wherein Y is O or S. In a particular embodiment, the AB ring is

[0205] In another embodiment, ring C is phenyl, optionally substituted by 1, 2, 3, 4 or 5 groups each independently selected from R X1 substituted by a group.

[0206] In one embodiment, L 1 In another embodiment, L 1 is a C1-C6 hydrocarbon chain. In a preferred embodiment, L 1 It is a C1-C2 hydrocarbon chain.

[0207] In one embodiment, the AB ring system is The C ring is absent and L 1 Does not exist.

[0208] In an alternative embodiment, the B ring and the C ring of the compound of formula (III) are further connected by L 2 Connected to obtain a variant of the compound of formula (III), which has the following structure (III'):

[0209]

[0210] in:

[0211] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0212] R 1 H, =O, or OR 7 ;

[0213] L 1 is a bond, or is a C1-C2 hydrocarbon chain;

[0214] L 2 is a bond, or is a C1-C2 hydrocarbon chain;

[0215] The premise is L 1 and L 2 Not a key at the same time;

[0216] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0217] A ring, B ring, R 2 、n、R X1 As defined in formula (III).

[0218] In one embodiment, R 1 For H.

[0219] In another embodiment, R 2 It is -OH.

[0220] In one embodiment, R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl).

[0221] The structure described by the following formula (IV) falls within the scope of the structures described by formula (I) and formula (III). In another aspect of the present invention, there is provided a compound of formula (IV), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases.

[0222]

[0223] in:

[0224] Y is O or S;

[0225] X is O;

[0226] R 9 Selected from H, halogen, C 1-6 Alkyl, C3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, -OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 wherein the alkyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 and -S(=O)R a2 substituted by a substituent; wherein R a1 、R b1 、R a2 、R b2 As defined in formula (III);

[0227] R 10 Selected from H, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 alkyl;

[0228] R 3 Selected from H, halogen, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2 is substituted with a substituent;

[0229] R 4 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-SR 7 、-NR 7 R 8 ; R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl) is substituted; wherein R 7 、R 8 As defined in formula (III);

[0230] R 5 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl) is substituted with a substituent;

[0231] R 6 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -O(benzyl), -SH, -S(C 1-6 alkyl), -S(benzyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, -NH(benzyl), wherein the alkyl or benzyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2 is substituted with a substituent;

[0232] The premise is that when R 4 -O(C 1-6 alkyl) and R 5 When it is a halogen, R 10 Not CF3.

[0233] In one embodiment, Y is O. When Y is O, formula (IV) is

[0234] In one embodiment, R 9 Selected from H, halogen, C 1-6 Alkyl, -OR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-S(=O)2NR a1 R b1 wherein the alkyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2、-C(=O)NR a2 R b2 、-C(=O)R a2 In one embodiment, R 9 Selected from H, halogen, -OR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 In one embodiment, R 9 For-OR a1 or -NR a1 R b1 In another embodiment, R 9 -C(=O)OR a2 or -C(=O)NR a2 R b2 In a particular embodiment, R 9 -NHC(=O)(C 1-6 In a particular embodiment, R 9 It is -NHC(=O)CH3.

[0235] In one embodiment, R 10 is selected from H, halogen or methyl. In another embodiment, R 10 For H.

[0236] In one embodiment, R a1 、R b1 Each occurrence is independently selected from H, C 1-6 Alkyl, -C(=O)R Y1 wherein the alkyl group is optionally substituted by one or more selected from halogen, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 Wherein R Y1 、R Y3 、R Y4 As defined in formula (III). In one embodiment, R a1 、R b1 Each occurrence is independently selected from H, C 1-6 Alkyl, -C(=O)(C 1-6 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -OH, -O(C1-6 alkyl), -O(C 3-6 Cycloalkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -C(=O)(C 1-6 alkyl), -C(=O)O(C 1-6 alkyl), -C(=O)O(C 3-6 Cycloalkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 In one embodiment, R a1 、R b1 Each occurrence is independently selected from H and C 1-6 alkyl.

[0237] In one embodiment, R a2 、R b2 Each occurrence is independently selected from H, C 1-6 alkyl.

[0238] In one embodiment, R 3 Selected from H, -OH, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -SH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 In one embodiment, R 3 is selected from H, halogen, methyl, -OH, -NH2, -NHCH3, wherein the methyl group is optionally selected from halogen, -OH, -NH2, -NH(C 1-2 In one embodiment, R 3is selected from H, halogen, methyl, -OH, -NH2, -NHCH3, wherein the methyl group is optionally substituted with a substituent selected from halogen, -OH, -OCH3, -NH2, -NHCH3. In one embodiment, R 3 is selected from H, halogen, methyl, -OH, -NH2. In one embodiment, R 3 In another embodiment, R 3 is selected from H, F, methyl, -OH, -NH2. In a particular embodiment, R 3 is selected from H, methyl, -OH. In another particular embodiment, R 3 is H. In another particular embodiment, R 3 In another embodiment, R 3 It is dimethylaminomethyl.

[0239] In one embodiment, R 4 Selected from H, -OR 7 、-SR 7 、-NR 7 R 8 ; R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 In one embodiment, R 4 C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -COOH, -C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 In a particular embodiment, R 4 In another embodiment, R 4 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 In one embodiment, R 4 Selected from H, halogen, C 1-3 Alkyl, -OH, -O(C 1-3 alkyl), -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 alkyl)2 and -COOH, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 alkyl)2 and -COOH substituents.

[0240] In one embodiment, R 5 Selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4In another embodiment, R 5 Selected from H, halogen, C 1-3 Alkyl, -OH, -O(C 1-3 alkyl), -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 alkyl)2 and -COOH, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 5 Selected from H, halogen, C 1-3 Alkyl, -OH, -O(C 1-3 alkyl), -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 5 It is dimethylaminomethyl.

[0241] In one embodiment, R 6 Selected from H, halogen, C 1-6 Alkyl, -OH, -NH2, wherein the alkyl is optionally substituted with one or more substituents selected from halogen, -OH, -NH2. In one embodiment, R 6 Selected from H, F, Cl, Br, C 1-6 Alkyl, -OH, -NH2, wherein the alkyl is optionally substituted with one or more substituents selected from halogen, -OH, -NH2. In one embodiment, R 6 is selected from H, F, Cl, Br, methyl, -OH, -NH2. In one embodiment, R 6 It is H or -OH.

[0242] In one embodiment, R 3 is a methyl group, and R 4 Selected from -OH, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -COOH substituted C 1-3 Alkyl, wherein the substituted C 1-3 The alkyl group is replaced by one or more selected from -OH, -NH2, -NH(C 1-2Alkyl), -N(C 1-2 In one embodiment, R 3 is a methyl group, and R 4 Selected from -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -COOH substituted C 1-3 Alkyl, wherein the substituted C 1-3 The alkyl group is replaced by one or more selected from -OH, -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 alkyl)2 and -COOH substituents.

[0243] In another embodiment, R 3 is a methyl group, and R 5 Selected from -OH, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -COOH substituted C 1-3 Alkyl, wherein the substituted C 1-3 The alkyl group is replaced by one or more selected from -OH, -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 In another embodiment, R 3 is a methyl group, and R 5 Selected from -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -COOH substituted C 1-3 Alkyl, wherein the substituted C 1-3 The alkyl group is replaced by one or more selected from -OH, -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 alkyl)2 and -COOH substituents.

[0244] The structure described by the following formula (V) falls within the scope of the structures described by formula (I), formula (III) and formula (IV). In another aspect of the present invention, there is provided a compound of formula (V), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases.

[0245]

[0246] in:

[0247] Y, R 9 、R 10、R 3 、R 4 、R 5 、R 6 As defined in formula (IV);

[0248] In one embodiment, Y is O. When Y is O, formula (V) is

[0249] In a particular embodiment, the compound of formula (V) is

[0250] The structure described by the following formula (VI) falls within the scope of the structures described by formula (I) and formula (III). In another aspect of the present invention, there is provided a compound of formula (VI), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases.

[0251]

[0252] in:

[0253] Ring B is a saturated or unsaturated six-membered heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0254] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0255] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0256] R 2 Selected from H, halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, =O, =S, =NR a1 、-OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NRa1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 、-C(=S)OR a1 、-C(=S)NR a1 R b1 、-C(=S)R a1 、-P(=O)(OR a1 )OR b1 、-C(=NR a1 )NR b1 R c1 , -OCN, -SCN, -N=C=O, -NCS, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, =O, =S, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 、-S(=O)R a2 and -C(=NR a2 )NR b2 R c2 Substituents substituted;

[0257] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0258] R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OR7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl, alkenyl or alkynyl groups are optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven membered heterocyclic)2, =O, -COOH and C 1-6 Substitution of alkyl groups;

[0259] R 7、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl) is substituted with a substituent;

[0260] R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 、-S(=O)2OR Y1、-S(=O)2R Y1 、-S(=O)2NR Y1 R Y2 、-S(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, =O, =S, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 Substituents substituted;

[0261] R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -OH, -SH, -NH2, =O and -COOH substituents;

[0262] A ring, R 1 As defined in formula (III);

[0263] Provided that the compound of formula (VI) does not include the following structure:

[0264]

[0265] where R 4 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl).

[0266] In one embodiment, Ring B is a saturated or unsaturated six-membered heterocyclic ring containing one or two heteroatoms independently selected from N and O. In another embodiment, Ring B is a dihydropyrimidine. In a preferred embodiment, Ring B is selected from 1,6-dihydropyrimidine, 1,2-dihydropyrimidine, and 1,4-dihydropyrimidine.

[0267] In a more preferred embodiment, the AB ring system is wherein Y is O or S. In a particular embodiment, the AB ring is

[0268] In another embodiment, the B ring is 2H-pyran or 4H-pyran. In a preferred embodiment, the AB ring is wherein Y is O or S. In a particular embodiment, the AB ring is

[0269] In another embodiment, Ring C is phenyl, optionally substituted by 1, 2, 3, 4 or 5 each independently selected from R X1 substituted by a group.

[0270] In one embodiment, L 1 In another embodiment, L 1 is a C1-C6 hydrocarbon chain. In a preferred embodiment, L 1 It is a C1-C2 hydrocarbon chain.

[0271] In yet another embodiment, R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, =O, =S, -OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 and -S(=O)R a2 In another embodiment, R 2 Selected from H, halogen, -NO2, -CN, =O, =S, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -O(C=O)(C 1-6 alkyl), -O(C=O)(C 3-6 Cycloalkyl), -O(C=O)(C 1-4 Alkylene-C 3-6 Cyclic hydrocarbon group), -O(C=O) (three to seven membered heterocyclic group), -O(C=O) (C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven-membered heterocyclic group)2, -NH(C=O)(C 1-6 Alkyl), -NH(C=O)(C 3-6 Cycloalkyl), -NH(C=O)(C 1-4 Alkylene-C 3-6 Cycloalkyl), -NH(C=O)(three-membered to seven-membered heterocyclic group), -C(=O)(C 1-6 alkyl), -COOH, -C(=O)O(C 1-6 alkyl), -C(=O)O(C 3-6 Cycloalkyl), -C(=O)O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -C(=O)O(three- to seven-membered heterocyclic group), -C(=O)O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -C(=O)NH2, -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -C(=O)NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -C(=O)N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -C(=O)NH(three- to seven-membered heterocyclic group), -C(=O)N(three- to seven-membered heterocyclic group), -C(=O)NH(C 1-4 Alkylene-three to seven-membered heterocyclic group), -C(=O)N(C 1-4 alkylene-three to seven membered heterocyclyl) 2, wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl or heterocyclyl is optionally substituted with one or more substituents selected from halogen, nitro, cyano, -OH, -SH, -NH2 and -COOH. In another embodiment, R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, -OR a1 、-SRa1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 wherein the alkyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 In a preferred embodiment, R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -NR a2 R b2 In a more preferred embodiment, R 2 Selected from H, halogen, C 1-6 Alkyl, -OH, wherein the alkyl is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and -NR a2 R b2 In a further embodiment, R 2 Selected from H, C 1-4 Alkyl, -OH, wherein the alkyl is optionally substituted with one or more selected from -NR a2 R b2 In a particular embodiment, R 2 Selected from H, C 1-4 Alkyl, -OH, wherein the alkyl is -CH2[CH(CH3)2], and is optionally substituted by one or more selected from -NR a2 R b2 In another embodiment, R 2 For the NR a1 R b1 In a particular embodiment, R2 for

[0272] In one embodiment, R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 In a preferred embodiment, R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-SR 7 、-NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 wherein the alkyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 In a preferred embodiment, R X1 and R X2 Each occurrence is independently selected from halogen, C 1-6 Alkyl, -OR 7 、-NR 7 R 8 , more preferably each independently selected from halogen, -OR 7 wherein the alkyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6Alkyl), -N(C 1-6 In a more preferred embodiment, R X1 and R X2 Each occurrence is independently selected from F, Cl, Br, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, optionally substituted C 1-6 Alkyl, wherein the optionally substituted C 1-6 The alkyl group is optionally substituted with one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 In a particular embodiment, R X1 and R X2 Each occurrence is independently selected from F, Cl, Br, methyl, -OH, dimethylaminomethyl.

[0273] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, wherein the alkyl, alkenyl, alkynyl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 In a preferred embodiment, R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 In a particular embodiment, R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -N(C 1-6 In another particular embodiment, R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -N(C 1-6 alkyl)2 is substituted with a substituent.

[0274] In one embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 In a preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -OR Y3 and -NR Y3 R Y4 In another preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally substituted by one or more selected from halogen, -OR Y3 and -NR Y3 R Y4 In a more preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2、-C(=O)R Y1 wherein the alkyl group is optionally substituted by one or more selected from halogen, -OR Y3 and -NR Y3 R Y4 In a further embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally substituted by one or more selected from halogen, -NR Y3 R Y4 In a particular embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-3 Alkyl, -OH, p-methylbenzoyl; wherein the alkyl is optionally substituted by one or more groups selected from halogen, -NH2.

[0275] In another embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -SH, -NH2, -COOH and C 1-6 In a preferred embodiment, R Y1 、R Y2 、R Y3 、R Y4Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, phenyl, phenyl-C 1-4 alkyl, five-membered to six-membered heteroaryl, five-membered to six-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -SH, -NH2, -COOH and C 1-6 In a more preferred embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-6 Alkyl, phenyl, phenyl-C 1-4 alkyl, five-membered to six-membered heteroaryl, five-membered to six-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl or phenyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -SH, -NH2, -COOH and C 1-6 In a more preferred embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-6 Alkyl, phenyl, phenyl-C 1-4 Alkyl, wherein the alkyl or phenyl group is optionally substituted by one or more selected from halogen, C 1-6 In a particular embodiment, R Y1 、R Y2 、R Y3 、R Y4 is independently selected at each occurrence from H and p-methylphenyl.

[0276] In another embodiment, R 2 Selected from H, halogen, -NO2, -CN, =O, =S, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, -OH, -O(C 1-6alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -O(C=O)(C 1-6 alkyl), -O(C=O)(C 3-6 Cycloalkyl), -O(C=O)(C 1-4 Alkylene-C 3-6 Cyclic hydrocarbon group), -O(C=O) (three to seven membered heterocyclic group), -O(C=O) (C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven-membered heterocyclic group)2, -NH(C=O)(C 1-6 Alkyl), -NH(C=O)(C 3-6 Cycloalkyl), -NH(C=O)(C 1-4 Alkylene-C 3-6 Cycloalkyl), -NH(C=O)(three-membered to seven-membered heterocyclic group), -C(=O)(C 1-6 alkyl), -C(=O)O(C 1-6 alkyl), -C(=O)O(C 3-6 Cycloalkyl), -C(=O)O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -C(=O)O(three- to seven-membered heterocyclic group), -C(=O)O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -C(=O)NH(C 1-6alkyl), -C(=O)N(C 1-6 alkyl)2, -C(=O)NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -C(=O)N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -C(=O)NH(three- to seven-membered heterocyclic group), -C(=O)N(three- to seven-membered heterocyclic group), -C(=O)NH(C 1-4 Alkylene-three to seven-membered heterocyclic group), -C(=O)N(C 1-4 alkylene-three to seven membered heterocyclyl)2, wherein the alkyl, alkylene, alkenyl, alkynyl, cycloalkyl or heterocyclyl is optionally substituted with one or more substituents selected from halogen, nitro, cyano, -OH, -SH, -NH2. In another embodiment, R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, -OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 wherein the alkyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 In a preferred embodiment, R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6Alkyl, -NR a2 R b2 In a more preferred embodiment, R 2 Selected from H, halogen, C 1-6 Alkyl, -OH, wherein the alkyl is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and -NR a2 R b2 In a further embodiment, R 2 Selected from H, C 1-4 Alkyl, -OH, wherein the alkyl is optionally substituted with one or more selected from -NR a2 R b2 In a particular embodiment, R 2 Selected from H, C 1-4 Alkyl, -OH, wherein the alkyl is -CH2[CH(CH3)2], and is optionally substituted by one or more selected from -NR a2 R b2 In another embodiment, R 2 For the NR a1 R b1 In a particular embodiment, R 2 for

[0277] In one embodiment, R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 In a preferred embodiment, R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-SR 7 、-NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 wherein the alkyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 In a preferred embodiment, R X1 and R X2 Each occurrence is independently selected from halogen, C 1-6 Alkyl, -OR 7 、-NR 7 R 8 , more preferably each independently selected from halogen, -OR 7 wherein the alkyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 In a more preferred embodiment, R X1 and R X2 Each occurrence is independently selected from F, Cl, Br, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, optionally substituted C 1-6 Alkyl, wherein the optionally substituted C 1-6 The alkyl group is optionally substituted with one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 In a particular embodiment, R X1 and R X2 Each occurrence is independently selected from F, Cl, Br, methyl, -OH, dimethylaminomethyl.

[0278] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, wherein the alkyl, alkenyl, alkynyl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 In a preferred embodiment, R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 In a particular embodiment, R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -N(C 1-6 In another particular embodiment, R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -N(C 1-6 alkyl)2 is substituted with a substituent.

[0279] In one embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、Rc2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 In a preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -OR Y3 and -NR Y3 R Y4 In another preferred embodiment, R a1 、R b1 、R c1 、Ra2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally substituted by one or more selected from halogen, -OR Y3 and -NR Y3 R Y4 In a more preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally substituted by one or more selected from halogen, -OR Y3 and -NR Y3 R Y4 In a further embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally substituted by one or more selected from halogen, -NR Y3 R Y4 In a particular embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-3 Alkyl, -OH, p-methylbenzoyl; wherein the alkyl is optionally substituted by one or more groups selected from halogen, -NH2.

[0280] In another embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -SH, -NH2 and C 1-6 In a preferred embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, phenyl, phenyl-C 1-4 alkyl, five-membered to six-membered heteroaryl, five-membered to six-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -SH, -NH2 and C 1-6 In a more preferred embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-6 Alkyl, phenyl, phenyl-C 1-4 alkyl, five-membered to six-membered heteroaryl, five-membered to six-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl or phenyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -SH, -NH2 and C 1-6 In a more preferred embodiment, R Y1 、R Y2 、R Y3 、RY4 Each occurrence is independently selected from H, C 1-6 Alkyl, phenyl, phenyl-C 1-4 Alkyl, wherein the alkyl or phenyl group is optionally substituted by one or more selected from halogen, C 1-6 In a particular embodiment, R Y1 、R Y2 、R Y3 、R Y4 is independently selected at each occurrence from H and p-methylphenyl.

[0281] In one embodiment, R 3 、R 6 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 In a preferred embodiment, R 3 、R 6 Each is independently selected from H, halogen, -OH, more preferably H or -OH.

[0282] In one embodiment, R 4 、R 5 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -NH(C 1-4 Alkylene-C3-6 Cycloalkyl), -NH (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -COOH, -C(=O)O(C 1-6 alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 In another embodiment, R 4 、R 5 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 In another embodiment, R 4 、R 5 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 In another embodiment, R 4 、R 5 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH2, -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), =O or substituted by a substituent.

[0283] The structure described by the following formula (VII) falls within the scope of the structures described by formula (I), formula (III) and formula (VI). In another aspect of the present invention, there is provided a compound of formula (VII), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases.

[0284]

[0285] in:

[0286] X is O;

[0287] Y, R 3 、R 4 、R 5 、R 6 As defined in formula (VI);

[0288] The C ring is where R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 ; where R 7 、R 8 As defined in formula (VI);

[0289] R 2 Selected from H, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, wherein the alkyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 and -S(=O)R a2 substituted by a substituent; wherein R a2 、R b2 、R c2 As defined in formula (VI);

[0290] Provided that the compound of formula (VII) does not include the following structure:

[0291]

[0292] where R 4 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl).

[0293] In one embodiment, Y is O. When Y is O, formula (VII) is

[0294] In one embodiment, R 2 Selected from H, halogen, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 and -S(=O)R a2 In one embodiment, R 2 Select from -OR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 In another embodiment, R 2 Selected from H, halogen, C 1-6 Alkyl, wherein the alkyl is optionally substituted with one or more substituents selected from halogen, -NO2, -CN, -OH, -NH2 and -COOH.

[0295] In one embodiment, R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 In a preferred embodiment, R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2 group substitution.

[0296] In one embodiment, R 3 Selected from H, halogen, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 In one embodiment, R 3 Selected from H, halogen, C 1-3 Alkyl, -OH, -O(C 1-3 alkyl), -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 3is selected from H, halogen, methyl, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, wherein the methyl group is optionally selected from halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 3 is selected from H, halogen, methyl, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, wherein the methyl group is optionally substituted with a substituent selected from halogen, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2. In one embodiment, R 3 is selected from H, halogen, methyl, -OH, -NH2, -N(CH3)2. In another embodiment, R 3 Selected from H, halogen, C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 In one embodiment, R 3 is selected from H, halogen, methyl, -OH, -OCH3, -NH2, -NHCH3, wherein the methyl group is optionally selected from halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 In one embodiment, R 3 is selected from H, halogen, methyl, -OH, -OCH3, -NH2, -NHCH3, wherein the methyl group is optionally substituted with a substituent selected from halogen, -OH, -OCH3, -NH2, -NHCH3. In another embodiment, R 3 Selected from H, halogen, C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), -NH2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-4 In one embodiment, R 3 is selected from H, halogen, methyl, -OH, -OCH3, -NH2, wherein the methyl group is optionally selected from halogen, -OH, -O(C 1-2 In one embodiment, R 3is selected from H, halogen, methyl, -OH, -OCH3, -NH2, wherein the methyl group is optionally substituted with a substituent selected from halogen, -OH, -OCH3, -NH2. 3 is selected from H, halogen, methyl, -OH, -NH2. In another embodiment, R 3 Selected from H, halogen, C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -OH, -O(C 1-4 In one embodiment, R 3 is selected from H, halogen, methyl, -OH, -OCH3, wherein the methyl group is optionally selected from halogen, -OH, -O(C 1-2 In one embodiment, R 3 is selected from H, halogen, methyl, -OH, -OCH3, wherein the methyl group is optionally substituted with a substituent selected from halogen, -OH, -OCH3. 3 is selected from H, halogen, methyl, -OH. In another embodiment, R 3 Selected from H, halogen, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more halogens, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 In one embodiment, R 3 is selected from H, halogen, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, substituted methyl, wherein the substituted methyl is selected from halogen, -OH, -O(C 1-2 Alkyl), -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 3 is selected from H, halogen, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, substituted methyl, wherein the substituted methyl is substituted with a substituent selected from halogen, -OH, -OCH3, -NHCH3, -N(CH3)2. In one embodiment, R 3 is selected from H, halogen, -OH, -NH2, methyl, wherein the methyl group is substituted by -N(CH3)2. In another embodiment, R3 Selected from H, halogen, -OH, -O(C 1-4 Alkyl), substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more halogens, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 In one embodiment, R 3 is selected from H, halogen, -OH, -OCH3, substituted methyl, wherein the substituted methyl is selected from halogen, -OH, -O(C 1-2 Alkyl), -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 3 is selected from H, halogen, -OH, -OCH3, substituted methyl, wherein the substituted methyl is substituted with a substituent selected from halogen, -OH, -OCH3, -NHCH3, -N(CH3)2. In one embodiment, R 3 is selected from H, halogen, -OH, methyl, wherein the methyl group is substituted by -N(CH3)2. In another embodiment, R 3 Selected from H, halogen, -OH, -O(C 1-4 Alkyl), substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more radicals selected from halogen, -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 In one embodiment, R 3 Selected from H, halogen, -OH, C 1-2 Alkyl, wherein the alkyl is substituted by one or more radicals selected from halogen, -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 3 is selected from H, halogen, -OH, methyl, wherein the methyl is selected from halogen, -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 3 is selected from H, halogen, -OH, methyl, wherein the methyl group is substituted with a substituent selected from halogen, -NHCH3, -N(CH3)2. In one embodiment, R 3 is selected from H, halogen, -OH, methyl, wherein the methyl group is substituted by -N(CH3)2. In another embodiment, R 3 Selected from H, halogen, -OH, -O(C1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more halogens, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 In one embodiment, R 3 is selected from H, halogen, -OH, -OCH3, -NH2, -NHCH3, substituted methyl, wherein the substituted methyl is selected from halogen, -OH, -O(C 1-2 Alkyl), -NH(C 1-2 In one embodiment, R 3 is selected from H, halogen, -OH, -OCH3, -NH2, -NHCH3, substituted methyl, wherein the substituted methyl is substituted by a substituent selected from halogen, -OH, -OCH3, -NHCH3. In one embodiment, R 3 is selected from H, halogen, -OH, -NH2, methyl, wherein the methyl group is substituted by -N(CH3)2. In another embodiment, R 3 Selected from H, halogen, -OH, -O(C 1-4 Alkyl), substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more halogens, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 In one embodiment, R 3 is selected from H, halogen, -OH, -OCH3, substituted methyl, wherein the substituted methyl is selected from halogen, -OH, -O(C 1-2 Alkyl), -NH(C 1-2 In one embodiment, R 3 is selected from H, halogen, -OH, -OCH3, substituted methyl, wherein the substituted methyl is substituted by a substituent selected from halogen, -OH, -OCH3, -NHCH3. In one embodiment, R 3 is selected from H, halogen, -OH, methyl, wherein the methyl group is substituted by -N(CH3)2. In another embodiment, R 3 Selected from H, halogen, -OH, -O(C 1-4 Alkyl), substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more radicals selected from halogen, -NH2, -NH(C 1-4 In one embodiment, R3 Selected from H, halogen, -OH, C 1-2 Alkyl, wherein the alkyl is substituted by one or more radicals selected from halogen, -NH(C 1-2 In one embodiment, R 3 is selected from H, halogen, -OH, methyl, wherein the methyl is selected from halogen, -NH(C 1-2 In one embodiment, R 3 is selected from H, halogen, -OH, methyl, wherein the methyl group is substituted with a substituent selected from halogen, -NHCH3. In one embodiment, R 3 In another embodiment, R 3 is selected from H, F, methyl, -OH, -NH2. In one embodiment, R 3 is H. In one embodiment, R 3 In one embodiment, R 3 For CH3.

[0297] In one embodiment, R 4 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 In one embodiment, R 4 Selected from H, halogen, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more halogens, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 In one embodiment, R 4 Selected from H, halogen, -OH, -O(C 1-3 alkyl), -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, substituted C 1-3Alkyl, wherein the substituted C 1-3 The alkyl group is optionally substituted with one or more radicals selected from halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 4 Selected from H, halogen, -OH, -NH2, -NH(C 1-4 Alkyl), substituted C 1-4 Alkyl, substituted-O(C 1-4 alkyl), substituted-N(C 1-4 alkyl)2, wherein the substituted C 1-4 Alkyl, substituted-O(C 1-4 Alkyl) and substituted-N(C 1-4 Alkyl)2 is replaced by one or more selected from halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-4 In one embodiment, R 4 Selected from H, halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 Alkyl), substituted C 1-2 Alkyl, substituted-O(C 1-2 alkyl), wherein the substituted C 1-2 Alkyl and substituted -O(C 1-2 Alkyl) is replaced by one or more selected from halogen, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 In one embodiment, R 4 Selected from H, halogen, -OH, -OCH3, -NH2, -NHCH3, substituted C 1-2 Alkyl, wherein the substituted C 1-2 The alkyl group is substituted with one or more substituents selected from halogen, -OH, -OCH3, -NH2, -NHCH3. 4 Selected from H, halogen, -OH, -NH2, -NH(C 1-4 Alkyl), substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more halogens, -OH, -OCH3, -NH2, -NH(C 1-4 In one embodiment, R 4 Selected from H, halogen, -OH, -NH2, -NH(C 1-2 Alkyl), -N(C 1-2Alkyl)2, substituted C 1-2 Alkyl, wherein the substituted C 1-2 The alkyl group is replaced by one or more halogens, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 In one embodiment, R 4 Selected from H, halogen, -OH, -NH2, -NHCH3, substituted C 1-2 Alkyl, wherein the substituted C 1-2 The alkyl group is substituted with one or more substituents selected from halogen, -OH, -OCH3, -NH2, -NHCH3. 4 Selected from H, halogen, C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 In one embodiment, R 4 Selected from H, halogen, C 1-2 Alkyl, -OH, -OCH3, wherein the alkyl group is optionally substituted with one or more substituents selected from halogen, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2. In one embodiment, R 4 Selected from H, halogen, C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-4 In one embodiment, R 4 Selected from H, halogen, C 1-2 Alkyl, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, wherein the alkyl is optionally substituted with one or more substituents selected from halogen, -OH, -OCH3. In one embodiment, R 4 Selected from H, halogen, C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -OH, -O(C 1-4 In one embodiment, R 4 Selected from H, halogen, C 1-2Alkyl, -OH, -OCH3, wherein the alkyl group is optionally substituted with one or more substituents selected from halogen, -OH, -OCH3. In one embodiment, R 4 In one embodiment, R 4 is H. In one embodiment, R 4 It is -OH.

[0298] In one embodiment, R 5 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 In one embodiment, R 5 Selected from H, halogen, C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 In one embodiment, R 5 Selected from H, halogen, -OH, -O(C 1-4 alkyl), -NH2, -NH(C1-4 Alkyl), -N(C 1-4 alkyl)2, -C(=O)O(C 1-4 alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 alkyl), -C(=O)N(C 1-4 alkyl)2, -OC(=O)(C 1-4 alkyl), -NC(=O)(C 1-4 alkyl)2, -C(=O)(C 1-4 Alkyl), substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more halogens, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 alkyl)2, -C(=O)O(C 1-4 alkyl), -C(=O)NH2, -C(=O)NH(C 1-4 alkyl), -C(=O)N(C 1-4 alkyl)2, -OC(=O)(C 1-4 alkyl), -NC(=O)(C 1-4 alkyl)2, -C(=O)(C 1-4 In one embodiment, R 5 Selected from H, halogen, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, substituted C 1-4 Alkyl, wherein the substituted C 1-4 The alkyl group is replaced by one or more halogens, -OH, -O(C 1-4 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 In one embodiment, R 5 Selected from H, halogen, -O(C 1-4 Alkyl), -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, substituted C 1-2 Alkyl, wherein the substituted C 1-2 The alkyl group is replaced by one or more selected from halogen, -O(C 1-4 Alkyl), -NH(C 1-4 Alkyl), -N(C 1-4 In one embodiment, R 5 Selected from H, halogen, -O(C1-4 Alkyl), -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, substituted C 1-2 Alkyl, wherein the substituted C 1-2 The alkyl group is substituted with one or more substituents selected from halogen, -OCH3, -NHCH3, -N(CH3)2. 5 Selected from H, halogen, -O(C 1-2 Alkyl), -NH(C 1-2 Alkyl), -N(C 1-2 Alkyl)2, substituted C 1-2 Alkyl, wherein the substituted C 1-2 The alkyl group is substituted with one or more substituents selected from halogen, -OCH3, -NHCH3, -N(CH3)2.

[0299] In one embodiment, R 6 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 In another embodiment, R 6 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more substituents selected from halogen, -OH, -NH 2. In one embodiment, R 6 Selected from H, halogen, -NO2, -CN, C 1-2 Alkyl, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 alkyl) 2, wherein the alkyl is optionally substituted with one or more substituents selected from halogen, -OH, -NH 2. In another embodiment, R 6 Selected from H, halogen, -NO2, -CN, C 1-4 Alkyl, -OH, -O(C 1-4 alkyl), -NH2, -NH(C1-4 Alkyl), -N(C 1-4 In another embodiment, R 6 Selected from H, halogen, -NO2, -CN, C 1-2 Alkyl, -OH, -O(C 1-2 alkyl), -NH2, -NH(C 1-4 Alkyl), -N(C 1-4 In one embodiment, R 6 Selected from H, F, Cl, Br, C 1-6 Alkyl, -OH, -NH2, wherein the alkyl is optionally substituted with one or more substituents selected from halogen, -OH, -NH2. In another embodiment, R 6 is selected from H, F, Cl, Br, methyl, -OH, -NH2. In a particular embodiment, R 6 is H or -OH, especially H.

[0300] In one embodiment, R 3 is a methyl group, and R 4 Selected from -OH, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -COOH substituted C 1-3 Alkyl, wherein the substituted C 1-3 The alkyl group is replaced by one or more selected from -OH, -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 In one embodiment, R 3 is a methyl group, and R 4 Selected from -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -COOH substituted C 1-3 Alkyl, wherein the substituted C 1-3 The alkyl group is replaced by one or more selected from -OH, -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 alkyl)2 and -COOH substituents.

[0301] In another embodiment, R 3 is a methyl group, and R 5 Selected from -OH, -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -COOH substituted C 1-3 Alkyl, wherein the substituted C 1-3The alkyl group is replaced by one or more selected from -OH, -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 In another embodiment, R 3 is a methyl group, and R 5 Selected from -NH2, -NH(C 1-3 Alkyl), -N(C 1-3 Alkyl)2, -COOH substituted C 1-3 Alkyl, wherein the substituted C 1-3 The alkyl group is replaced by one or more selected from -OH, -NH2, -NH(C 1-2 Alkyl), -N(C 1-2 alkyl)2 and -COOH substituents.

[0302] In one embodiment, R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -O(C=O)(C 1-6 alkyl), -O(C=O)(C 3-6 Cycloalkyl), -O(C=O)(C 1-4 Alkylene-C 3-6 Cyclic hydrocarbon group), -O(C=O) (three to seven membered heterocyclic group), -O(C=O) (C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven-membered heterocyclic group)2, -NH(C=O)(C 1-6 Alkyl), -NH(C=O)(C 3-6 Cycloalkyl), -NH(C=O)(C 1-4 Alkylene-C 3-6 Cycloalkyl), -NH(C=O)(three-membered to seven-membered heterocyclic group), -C(=O)(C 1-6 alkyl), -C(=O)O(C 1-6 alkyl), -C(=O)O(C 3-6 Cycloalkyl), -C(=O)O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -C(=O)O(three- to seven-membered heterocyclic group), -C(=O)O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -C(=O)NH2, -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -C(=O)NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -C(=O)N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -C(=O)NH(three- to seven-membered heterocyclic group), -C(=O)N(three- to seven-membered heterocyclic group), -C(=O)NH(C 1-4 Alkylene-three to seven-membered heterocyclic group), -C(=O)N(C 1-4 wherein said alkyl, alkylene, alkenyl, alkynyl, cycloalkyl or heterocyclyl is optionally substituted by one or more radicals selected from H, halogen, nitro, cyano, -OH, -SH, -NH2, =O and -COOH. In one embodiment, R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R7 、-NC(=O)R 7 R 8 、-C(=O)R 7 In one embodiment, R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -O(C=O)(C 1-6 alkyl), -O(C=O)(C 3-6 Cycloalkyl), -O(C=O)(C 1-4 Alkylene-C 3-6 Cyclic hydrocarbon group), -O(C=O) (three to seven-membered heterocyclic group), -O(C=O) (C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven-membered heterocyclic group)2, -NH(C=O)(C 1-6 Alkyl), -NH(C=O)(C 3-6 Cycloalkyl), -NH(C=O)(C 1-4 Alkylene-C 3-6 In one embodiment, R 14 、R 15 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -O(C3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -O(C=O)(C 1-6 alkyl), -O(C=O)(C 3-6 Cycloalkyl), -O(C=O)(C 1-4 Alkylene-C 3-6 Cyclic hydrocarbon group), -O(C=O) (three to seven-membered heterocyclic group), -O(C=O) (C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven-membered heterocyclic group)2, -NH(C=O)(C 1-6 Alkyl), -NH(C=O)(C 3-6 Cycloalkyl), -NH(C=O)(C 1-4 Alkylene-C 3-6 In one embodiment, R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -O(C=O)(C 1-6 alkyl), -O(C=O)(C 3-6 Cycloalkyl), -O(C=O)(C 1-4 Alkylene-C 3-6Cyclic hydrocarbon group), -O(C=O) (three to seven-membered heterocyclic group), -O(C=O) (C 1-4 In one embodiment, R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -O(C=O)(C 1-6 alkyl), -O(C=O)(C 3-6 Cycloalkyl), -O(C=O)(C 1-4 Alkylene-C 3-6 Cyclic hydrocarbon group), -O(C=O) (three to seven-membered heterocyclic group), -O(C=O) (C 1-4 In one embodiment, R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven-membered heterocyclic group)2, -NH(C=O)(C 1-6 Alkyl), -NH(C=O)(C 3-6 Cycloalkyl), -NH(C=O)(C 1-4 Alkylene-C 3-6 In one embodiment, R 14、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven-membered heterocyclic group)2, -NH(C=O)(C 1-6 Alkyl), -NH(C=O)(C 3-6 Cycloalkyl), -NH(C=O)(C 1-4 Alkylene-C 3-6 In one embodiment, R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C=O)(C 1-6 In one embodiment, R 14 、R 15 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C=O)(C 1-6 In one embodiment, R 16 is H. In one embodiment, R 16 It is -OCH3.

[0303] The structure described by the following formula (VIII) falls within the scope of the structures described by formula (I), formula (III), formula (VI) and formula (VII). In another aspect of the present invention, there is provided a compound of formula (VIII), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases.

[0304]

[0305] in:

[0306] C ring, Y, R 2 、R 3 、R 4 、R 5 、R 6 As defined in formula (VII).

[0307] In one embodiment, the C ring, Y, R 2 、R 3 、R 4 、R 5 、R 6 As defined in formula (VII);

[0308] Provided that the compound of formula (VIII) does not include the following structure:

[0309]

[0310] where R 4 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl).

[0311] In one embodiment, Y is O. When Y is O, formula (VIII) is

[0312] In a particular embodiment, the compound of formula (VIII) is selected from:

[0313]

[0314] The structure described by the following formula (IX) falls within the scope of the structures described by formula (I), formula (III) and formula (VI). In another aspect of the present invention, there is provided a compound of formula (IX), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases.

[0315]

[0316] in:

[0317] R 19 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -COOH substituents;

[0318] m is 0, 1, 2, 3, 4 or 5;

[0319] R 2 、R 3 、R 4 、R 5 、R 6 As defined in formula (VI).

[0320] In one embodiment, R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, -OR a1 、-SR a1 、-NR a1 R b1、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 wherein the alkyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 In a preferred embodiment, R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -NR a2 R b2 In a more preferred embodiment, R 2 Selected from H, halogen, C 1-6 Alkyl, -OH, wherein the alkyl is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and -NR a2 R b2 In a further embodiment, R 2 Selected from H, C 1-4 Alkyl, -OH, wherein the alkyl is optionally substituted with one or more selected from -NR a2 R b2 In a particular embodiment, R 2 Selected from H, C 1-4 Alkyl, -OH, wherein the alkyl is -CH2[CH(CH3)2], and is optionally substituted by one or more selected from -NR a2 R b2 In another embodiment, R 2 For the NR a1 R b1 Substituted alkyl. R a1 、R b1 、R c1 、Ra2 、R b2 、R c2 As defined in formula (VI). In a particular embodiment, R 2 for

[0321] In one embodiment, R 19 Each occurrence is independently selected from halogen, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2 is substituted with a substituent.

[0322] In a particular embodiment, the compound of formula (IX) is

[0323] In one aspect, the present invention provides a compound of formula (I'), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite or prodrug thereof, for use in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases.

[0324]

[0325] in:

[0326] Ring A is a benzene ring;

[0327] Ring B is a saturated or unsaturated six-membered heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0328] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0329] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0330] R 1 =Y, wherein Y is O or S;

[0331] R 2 Selected from H, halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, =O, =S, =NR a1 、-OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 、-C(=S)OR a1 、-C(=S)NR a1 R b1 、-C(=S)R a1 、-P(=O)(OR a1 )OR b1 、-C(=NR a1 )NR b1 R c1 , -OCN, -SCN, -N=C=O, -NCS, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, =O, =S, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 、-S(=O)R a2 and -C(=NRa2 )NR b2 R c2 Substituents substituted;

[0332] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0333] R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl, alkenyl or alkynyl group is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -SH, -NH2, =O, -COOH and C 1-6 Substitution of alkyl groups;

[0334] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 alkyl;

[0335] R a1 、R b1 、Rc1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 、-S(=O)2OR Y1 、-S(=O)2R Y1 、-S(=O)2NR Y1 R Y2 、-S(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from =O, =S, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 Substituents substituted;

[0336] R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, -C 3-10 Cycloalkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Substituents of alkynyl, -OH, -SH, -NH2, =O and -COOH.

[0337] In one embodiment, R 1 =O. In another embodiment, R 1 =S.

[0338] In one embodiment, Ring B is a saturated or unsaturated six-membered heterocyclic ring containing one or two heteroatoms independently selected from N and O. In another embodiment, Ring B is a dihydropyrimidine. In a preferred embodiment, Ring B is selected from 1,6-dihydropyrimidine, 1,2-dihydropyrimidine, and 1,4-dihydropyrimidine.

[0339] In a more preferred embodiment, the AB ring system is wherein Y is O or S. In a particularly preferred embodiment, the AB ring system is

[0340] In another embodiment, the B ring is 2H-pyran or 4H-pyran. In a preferred embodiment, the AB ring is wherein Y is O or S. In a particularly preferred embodiment, the AB ring system is

[0341] In another embodiment, Ring C is phenyl, optionally substituted by 1, 2, 3, 4 or 5 each independently selected from R X1 substituted by a group.

[0342] In one embodiment, L 1 In another embodiment, L 1 is a C1-C6 hydrocarbon chain. In a preferred embodiment, L 1 It is a C1-C2 hydrocarbon chain.

[0343] In yet another embodiment, R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C1-4 Alkyl, =O, =S, -OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, =O, =S, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 and -S(=O)R a2 In a preferred embodiment, R 2 Selected from H, halogen, -NO2, -CN, =O, =S, -COOH, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven-membered heterocyclic group)2, -C(=O)(C 1-6 alkyl), -COOH, -C(=O)O(C 1-6 alkyl), -C(=O)O(C 3-6 Cycloalkyl), -C(=O)O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -C(=O)O(three- to seven-membered heterocyclic group), -C(=O)O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -C(=O)NH2, -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -C(=O)NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -C(=O)N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -C(=O)NH(three- to seven-membered heterocyclic group), -C(=O)N(three- to seven-membered heterocyclic group), -C(=O)NH(C 1-4 Alkylene-three to seven-membered heterocyclic group), -C(=O)N(C 1-4 wherein said alkyl, alkylene, alkenyl, alkynyl, cycloalkyl or heterocyclyl is optionally substituted with one or more substituents selected from halogen, nitro, cyano, -OH, -SH, -NH, =O and -COOH. In another preferred embodiment, R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl and -NR a2 Rb2 In a more preferred embodiment, R 2 Selected from H, halogen, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and -NR a2 R b2 In a further preferred embodiment, R 2 H or C 1-4 Alkyl, wherein the alkyl is optionally substituted by one or more selected from -NR a2 R b2 In a particularly preferred embodiment, R 2 H or C 1-4 Alkyl, wherein the alkyl is -CH[CH(CH3)2]-, and is optionally substituted by one or more selected from -NR a2 R b2 substituted by a group.

[0344] In one embodiment, R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl, alkenyl or alkynyl group is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -SH, -NH2, =O, -COOH and C 1-6 In a preferred embodiment, R X1 and R X2Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-SR 7 、-NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 In a preferred embodiment, R X1 and R X2 Each occurrence is independently selected from halogen, C 1-6 Alkyl, -OR 7 、-NR 7 R 8 In a more preferred embodiment, R X1 and R X2 Each occurrence is independently selected from halogen, C 1-6 Alkyl, -OR 7 、-NR 7 R 8 In a further preferred embodiment, R X1 and R X2 is independently selected at each occurrence from halogen, -OR 7 In a more preferred embodiment, R X1 and R X2 Each occurrence is independently selected from Cl, Br, -OH, -O(C 1-6 In a particularly preferred embodiment, R X1 and R X2 is independently selected at each occurrence from Cl and -OH.

[0345] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 In a preferred embodiment, R 7 、R 8 Each occurrence is independently selected from H, C 1-6 In a particularly preferred embodiment, R 7 、R 8 Each occurrence is independently selected from H, C 1-6 alkyl.

[0346] In one embodiment, Ra1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 、-S(=O)2OR Y1 、-S(=O)2R Y1 、-S(=O)2NR Y1 R Y2 、-S(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from =O, =S, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 In a preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl, aryl or heteroaryl groups are optionally substituted by one or more groups selected from -OR Y3 and -NR Y3 R Y4 In another preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally replaced by one or more selected from -OR Y3 and -NR Y3 R Y4 In a more preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally replaced by one or more selected from -OR Y3 and -NR Y3 R Y4 In a further preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)RY1 wherein the alkyl group is optionally replaced by one or more selected from -NR Y3 R Y4 In a particularly preferred embodiment, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-3 Alkyl, -OH, p-methylbenzoyl; wherein the alkyl is optionally substituted by one or more groups selected from -NH2.

[0347] In another embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, -C 3-10 Cycloalkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -SH, -NH2, =O, -COOH and C 1-6 In a preferred embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, phenyl, phenyl-C 1-4 alkyl, five-membered to six-membered heteroaryl, five-membered to six-membered heteroaryl-C 1-4Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -SH, -NH2, -COOH and C 1-6 In a more preferred embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-6 Alkyl, phenyl, phenyl-C 1-4 alkyl, five-membered to six-membered heteroaryl, five-membered to six-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl or phenyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -SH, -NH2, -COOH and C 1-6 In a more preferred embodiment, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-6 Alkyl, phenyl, phenyl-C 1-4 Alkyl, wherein the alkyl or phenyl group is optionally substituted by one or more selected from halogen, C 1-6 In a particularly preferred embodiment, R Y1 、R Y2 、R Y3 、R Y4 is independently selected at each occurrence from H and p-methylphenyl.

[0348] In a particularly preferred embodiment, the compound of formula (I') is selected from:

[0349]

[0350] In another aspect, the present invention provides a use of a pharmaceutical composition of a compound of any one of Formula (I), (II), (III), (III'), (IV), (V), (VI), (VII), (VIII), (IX), and (I') in the preparation of a medicament for preventing or treating a polyQ-related neurodegenerative disease, wherein the pharmaceutical composition comprises a compound of any one of Formula (I), (II), (III), (III'), (IV), (V), (VI), (VII), (VIII), (IX), and (I'), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite, or prodrug thereof, and at least one pharmaceutically acceptable carrier.

[0351] In another aspect, the present invention provides a compound of any one of Formula (I), (II), (III), (III'), (IV), (V), (VI), (VII), (VIII), (IX), and (I'), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite, or prodrug thereof, or a pharmaceutical composition thereof, for use in preventing or treating polyQ-related neurodegenerative diseases.

[0352] In a further aspect, the present invention provides a method for preventing or treating a polyQ-related neurodegenerative disease, comprising administering to a subject in need thereof a compound of any one of Formula (I), (II), (III), (III'), (IV), (V), (VI), (VII), (VIII), (IX), and (I'), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite, or prodrug thereof, or a pharmaceutical composition thereof.

[0353] The compounds of the present invention can be administered orally or parenterally to a patient in the form of conventional preparations, such as capsules, microcapsules, tablets, granules, powders, lozenges, pills, suppositories, injections, suspensions, syrups, patches, creams, lotions, ointments, gels, sprays, solutions and emulsions. Suitable preparations can be prepared by commonly used methods using conventional organic or inorganic additives, such as excipients (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate), binders (e.g., cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose or starch), disintegrants (e.g., starch, carboxymethylcellulose, hydroxypropyl starch, low-substituted hydroxypropyl cellulose, sodium bicarbonate). , calcium phosphate or calcium citrate), lubricants (e.g., magnesium stearate, light anhydrous silicic acid, talc or sodium lauryl sulfate), flavoring agents (e.g., citric acid, menthol, glycine or orange powder), preservatives (e.g., sodium benzoate, sodium bisulfite, methylparaben or propylparaben), stabilizers (e.g., citric acid, sodium citrate or acetic acid), suspending agents (e.g., methylcellulose, polyvinylpyrrolidone or aluminum stearate), dispersants (e.g., hydroxypropyl methylcellulose), diluents (e.g., water) and base wax (e.g., cocoa butter, white petrolatum or polyethylene glycol). For example, the effective amount of the compound in the pharmaceutical composition can be an amount that can achieve the desired effect.

[0354] The dosage regimen can be adjusted to provide the optimal desired response. For example, when administered as an injectable, a single bolus, bolus, and / or continuous infusion can be administered, among others. For example, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. It should be noted that dosage values ​​can vary depending on the type and severity of the condition to be alleviated and can include single or multiple doses. Generally, the dosage for treatment varies, depending on considerations such as: the age, sex, and general health of the patient to be treated; the frequency of treatment and the nature of the desired effect; the extent of tissue damage; the duration of symptoms; and other variables that can be adjusted by the individual physician. It will be further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering or supervising the administration of the composition. The dosage and administration regimen of the pharmaceutical composition can be readily determined by one of ordinary skill in the clinical field. For example, the composition or compound of the present invention can be administered in divided doses from 4 times a day to once every 3 days, with the dosage amount being, for example, 0.01 to 1000 mg / dose. The required dose may be administered in one or more doses to achieve the desired result.The pharmaceutical composition according to the present invention may also be provided in unit dosage form.

[0355] In one embodiment, the present invention provides capsules containing a compound of the present invention without additional carriers.

[0356] The pharmaceutical compositions of the present invention may be in the form of tablets, chewable tablets, capsules, solutions, parenteral solutions, lozenges, suppositories, suspensions, etc. The compositions may be formulated to contain a daily dose or a suitable portion of a daily dose in a dosage unit which may be a single tablet or capsule or a suitable volume of liquid.

[0357] In one embodiment, the solution is prepared by a water-soluble salt, such as hydrochloride. Generally, all compositions are prepared according to known methods in pharmaceutical chemistry. Capsules can be prepared by mixing the compound with a suitable carrier or diluent and filling an appropriate amount of the mixture into a capsule. Commonly used carriers and diluents include, but are not limited to inert powdered substances, such as a variety of different starches, powdered cellulose, especially crystallized and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, cereal flour and similar edible powders.

[0358] Tablet can be prepared by direct compression, wet granulation or dry granulation. Its preparation usually adds diluent, binder, lubricant and disintegrant and this compound. Typical diluent includes, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or calcium sulfate, inorganic salt (such as sodium chloride) and powdered sugar. Powdered cellulose derivative is also useful. Typical tablet binder is following material, such as starch, gelatin and sugar (such as lactose, fructose, glucose etc.). Natural and synthetic gum is also suitable, and it includes gum arabic, alginate, methylcellulose, polyvinyl pyrrolidone etc. Polyethylene glycol, ethyl cellulose and wax can also serve as binder.

[0359] Lubricants can be selected from such slippery solids, such as talc, magnesium stearate and calcium stearate, stearic acid and hydrogenated vegetable oils. Tablet disintegrants swell when wetted so that the tablet breaks and releases the compound. They include starch, clay, cellulose, algin and gum. More particularly, for example corn and potato starch, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponges, anion exchange resins, alginic acid, guar gum, citrus pulp and carboxymethyl cellulose and sodium lauryl sulfate can be used. Tablets can be coated with sugar as flavorings and sealants, or coated with film-forming protective agents to optimize the dissolution properties of tablets. Compositions can also be formulated into chewable tablets, for example, by adding some substances in the formulation, such as mannitol formulations.

[0360] When it is desired to administer the drug as a suppository, a typical base can be used. Cocoa butter is a traditional suppository base, which can be modified by adding waxes to slightly raise its melting point. In particular, water-miscible suppository bases comprising polyethylene glycols of various molecular weights are widely used.

[0361] The effect of the compound can be delayed or prolonged by a suitable formulation. For example, slowly dissolving pellets of the compound can be prepared and added to tablets or capsules or as a sustained-release implantable device. This technology also includes preparing several pellets with different dissolution rates and using a mixture of pellets to fill capsules. Tablets or capsules can be coated with a film that resists dissolution over a predictable period. Even parenteral formulations can be made long-lasting by dissolving or suspending the compound in an oily or emulsified solvent that allows it to slowly disperse in the serum.

[0362] In a preferred embodiment, the polyQ-associated neurodegenerative disease is selected from spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 7, spinocerebellar ataxia type 12, spinocerebellar ataxia type 17, dentate-nigral-rubral-pallidum-subthalamic atrophy, Huntington's disease, and spinobulbar muscular atrophy. In another preferred embodiment, the polyQ-associated neurodegenerative disease is selected from spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 7, spinocerebellar ataxia type 12, and spinocerebellar ataxia type 17. In another preferred embodiment, the polyQ-associated neurodegenerative disease is selected from Huntington's disease, spinocerebellar ataxia type 1, and spinocerebellar ataxia type 3. In a specific embodiment, the polyQ-associated neurodegenerative disease is Huntington's disease. In another specific embodiment, the polyQ-associated neurodegenerative disease is spinocerebellar ataxia type 1 or spinocerebellar ataxia type 3.

[0363] The embodiments of the present invention can be listed as follows:

[0364] [1] Use of a compound of formula (I"), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite or prodrug thereof, in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases

[0365]

[0366] in:

[0367] Ring A is a benzene ring;

[0368] Ring B is a saturated or unsaturated five-membered or six-membered heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0369] The C ring is selected from C 6-10 Aryl and five- to ten-membered heteroaryl, the aryl or heteroaryl being optionally substituted by one or more independently selected from R X1 The group substitution;

[0370] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0371] Alternatively, the C ring is absent and L 1 does not exist;

[0372] R 1 =Y, where Y is O or S, or OR 7 ;

[0373] R 2 Each occurrence is independently selected from H, halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, =O, =S, =NR a1 、-OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 、-C(=S)OR a1 、-C(=S)NR a1 R b1 、-C(=S)R a1 、-P(=O)(OR a1 )OR b1 、-C(=NR a1 )NR b1 R c1 , -OCN, -SCN, -N=C=O, -NCS, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, =O, =S, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2Ra2 、-S(=O)2NR a2 R b2 、-S(=O)R a2 and -C(=NR a2 )NR b2 R c2 Substituents substituted;

[0374] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0375] R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl, alkenyl or alkynyl groups are optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C 1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven membered heterocyclic)2, =O, -COOH and C 1-6 Substitution of alkyl groups;

[0376] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl or aryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl) is substituted with a substituent;

[0377] R a1 、R b1 、R c1 、R a2 、R b2、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 、-S(=O)2OR Y1 、-S(=O)2R Y1 、-S(=O)2NR Y1 R Y2 、-S(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, =O, =S, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 Substituents substituted;

[0378] R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -OH, -SH, -NH2, =O and -COOH substituents;

[0379] n is 1 or 2;

[0380] Provided that the compound of formula (I") does not include the following structure:

[0381]

[0382] where R 3 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl); R 10 is H;

[0383] And the compound of formula (I") does not include the following structure:

[0384]

[0385] where R 4 -O(C 1-6 alkyl); R 5 is halogen; R 10 is CF3;

[0386] And the compound of formula (I") does not include the following structure:

[0387]

[0388] where R 4 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl);

[0389] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0390] And the compound of formula (I") does not include the following structure:

[0391]

[0392] where R 4 Selected from -OH, -O(C 1-6 alkyl); R 5is halogen; Ring C is a five- to ten-membered heteroaryl group, optionally substituted by one or more independently selected from R X1 substituted by a group.

[0393] [2] The use of the above-mentioned [1], wherein the compound of formula (I") has the structure of the following formula (II"):

[0394]

[0395] in:

[0396] Y is O or S;

[0397] Ring C is a five- to seven-membered heteroaryl group, wherein the heteroaryl group is optionally substituted by one or more independently selected from R X1 The group substitution;

[0398] R 2 Selected from H, C 1-8 alkyl;

[0399] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0400] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0401] where R X1 、R X2 As defined in [1] above.

[0402] [3] The use of the above-mentioned [1], wherein the compound of formula (I") has the structure of the following formula (IV"):

[0403]

[0404] in:

[0405] Y is O or S;

[0406] X is O;

[0407] R 9 Selected from H, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, -OR a1 、-SR a1 、-NR a1 R b1、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 wherein the alkyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 and -S(=O)R a2 substituted by a substituent; wherein R a1 、R b1 、R a2 、R b2 As defined in [1] above;

[0408] R 10 Selected from H, halogen, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 alkyl;

[0409] R 3 Selected from H, halogen, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, wherein the alkyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2 is substituted with a substituent;

[0410] R 4 Selected from H, halogen, -NO2, -CN, C 1-6Alkyl, -OR 7 、-SR 7 、-NR 7 R 8 ; R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl) is substituted; wherein R 7 、R 8 As defined in [1] above;

[0411] R 5 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), wherein the alkyl is optionally substituted by one or more radicals selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2, -C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6alkyl) is substituted with a substituent;

[0412] R 6 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -O(benzyl), -SH, -S(C 1-6 alkyl), -S(benzyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl) 2, -NH(benzyl), wherein the alkyl or benzyl is optionally substituted by one or more selected from halogen, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2 is substituted with a substituent;

[0413] The premise is that when R 4 -O(C 1-6 alkyl) and R 5 When it is a halogen, R 10 Not CF3.

[0414] [4] The use of the above-mentioned [1], wherein the compound of formula (I") has the structure of the following formula (VI"):

[0415]

[0416] in:

[0417] Ring B is a saturated or unsaturated six-membered heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0418] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0419] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0420] R 2 Selected from H, halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl-C 1-4 Alkyl, five-membered to ten-membered heteroaryl-C 1-4Alkyl, =O, =S, =NR a1 、-OR a1 、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 、-C(=S)OR a1 、-C(=S)NR a1 R b1 、-C(=S)R a1 、-P(=O)(OR a1 )OR b1 、-C(=NR a1 )NR b1 R c1 , -OCN, -SCN, -N=C=O, -NCS, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, =O, =S, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 、-S(=O)R a2 and -C(=NR a2 )NR b2 R c2 Substituents substituted;

[0421] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0422] R X1 and R X2 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl, alkenyl or alkynyl groups are optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -O(C 3-6 Cycloalkyl), -O(C 1-4 Alkylene-C 3-6 Cycloalkyl), -O(three-membered to seven-membered heterocyclic group), -O(C 1-4 Alkylene)-(three- to seven-membered heterocyclic group), -SH, -S(C 1-6 Alkyl), -S(C 3-6 Cycloalkyl), -S(C 1-4 Alkylene-C 3-6 Cycloalkyl), -S(three-membered to seven-membered heterocyclic group), -S(C 1-4 Alkylene)-(three to seven membered heterocyclic group), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C 3-6 Cycloalkyl), -N(C 3-6 Cycloalkyl)2, -NH(C 1-4 Alkylene-C 3-6 Cycloalkyl), -N(C 1-4 Alkylene-C 3-6 Cycloalkyl)2, -NH (three to seven membered heterocyclic group), -N (three to seven membered heterocyclic group), -NH (C1-4 Alkylene-three to seven-membered heterocyclic group), -N(C 1-4 Alkylene-three to seven membered heterocyclic)2, =O, -COOH and C 1-6 Substitution of alkyl groups;

[0423] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclic group is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2、-COOH、-C(=O)O(C 1-6 alkyl), -C(=O)NH(C 1-6 alkyl), -C(=O)N(C 1-6 alkyl)2, -OC(=O)(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -C(=O)(C 1-6 alkyl) is substituted with a substituent;

[0424] R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NRY1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 、-S(=O)2OR Y1 、-S(=O)2R Y1 、-S(=O)2NR Y1 R Y2 、-S(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, =O, =S, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 Substituents substituted;

[0425] R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -OH, -SH, -NH2, =O and -COOH substituents;

[0426] A ring, R 1 As defined in [1] above;

[0427] Provided that the compound of formula (VI") does not include the following structure:

[0428]

[0429] where R4 Selected from -O(C 1-6 alkyl), -O(C 1-4 Alkylene-C 6-10 aryl).

[0430] [5] The use of the above-mentioned [1], wherein the B ring is a dihydropyrimidine.

[0431] [6] The use of [1] above, wherein the B ring is 2H-pyran or 4H-pyran; preferably 2H-pyran.

[0432] [7] The use of any one of the above [1]-[6], wherein R 1 =O.

[0433] [8] The use of [5] above, wherein the AB ring system is

[0434] [9] The use of [6] above, wherein the AB ring system is

[0435]

[10] The use of any one of the above [4]-[9], wherein L 1 is a bond, or is a C1-C2 hydrocarbon chain.

[0436]

[11] The use of any one of the above [4]-

[10] , wherein the C ring is a phenyl group, and the phenyl group is optionally substituted by 1, 2, 3, 4 or 5 groups each independently selected from R X1 The group substitution;

[0437] Preferably, the C ring is where R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7

[0438] Preferably, R 14 、R 15 、R 16 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 ;

[0439] More preferably, R 14 、R 15 、R 17 、R 18 Each independently selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -NH(C=O)(C 1-6 alkyl); R 16 It is H or -OCH3.

[0440]

[12] The use of [4] above, wherein the compound of formula (VI") has the structure of the following formula (IX"):

[0441]

[0442] in:

[0443] R 19 Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -O(C 1-6 alkyl), -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -COOH substituents;

[0444] m is 0, 1, 2, 3, 4 or 5;

[0445] R 2 、R 3 、R 4 、R 5 、R 6 As defined above [4].

[0446]

[13] The use of any one of [1] to

[12] above, wherein the compound is selected from

[0447]

[0448]

[0449]

[14] Use of a pharmaceutical composition in the preparation of a medicament for preventing or treating PolyQ-related neurodegenerative diseases; the pharmaceutical composition comprises a compound of formula (I"), formula (II"), formula (III"), formula (III"), formula (IV"), formula (V"), formula (VI"), formula (VII"), formula (VIII"), formula (IX"), formula (X") or formula (XI") described in any one of [1] to

[13] above, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, and at least one pharmaceutically acceptable carrier.

[0450]

[15] The use of any one of the above [1]-

[14] , wherein the PolyQ-related neurodegenerative disease is selected from spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 7, spinocerebellar ataxia type 12, spinocerebellar ataxia type 17, dentate-nigral-rubral-pallidular-subthalamic atrophy, Huntington's disease and spinobulbar muscular atrophy, in particular Huntington's disease and spinocerebellar ataxia type 3.

[0451] The embodiments of the present invention can also be listed as follows:

[0452] <1> Use of a compound of formula (I'), or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope, metabolite or prodrug thereof, in the preparation of a medicament for preventing or treating PolyQ-related neurodegenerative diseases

[0453]

[0454] in:

[0455] Ring A is a benzene ring;

[0456] Ring B is a saturated or unsaturated six-membered heterocyclic ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S;

[0457] C ring is C 6-10 Aryl, optionally substituted by one or more independently selected from R X1 The group substitution;

[0458] L 1 is a bond, or is a C1-C6 hydrocarbon chain;

[0459] R 1 =Y, wherein Y is O or S;

[0460] R 2 Selected from H, halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, =O, =S, =NR a1 、-OR a1、-SR a1 、-NR a1 R b1 、-C(=O)OR a1 、-C(=O)NR a1 R b1 、-C(=O)R a1 、-S(=O)2OR a1 、-S(=O)2R a1 、-S(=O)2NR a1 R b1 、-S(=O)R a1 、-C(=S)OR a1 、-C(=S)NR a1 R b1 、-C(=S)R a1 、-P(=O)(OR a1 )OR b1 、-C(=NR a1 )NR b1 R c1 , -OCN, -SCN, -N=C=O, -NCS, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, =O, =S, -OR a2 、-SR a2 、-NR a2 R b2 、-C(=O)OR a2 、-C(=O)NR a2 R b2 、-C(=O)R a2 、-S(=O)2OR a2 、-S(=O)2R a2 、-S(=O)2NR a2 R b2 、-S(=O)R a2 and -C(=NR a2 )NR b2 R c2 Substituents substituted;

[0461] R 3 、R 4 、R 5 、R 6 Each independently selected from H and R X2 ;

[0462] R X1 and R X2Each occurrence is independently selected from halogen, -NO2, -CN, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OR 7 、-SR 7 、-NR 7 R 8 、-C(=O)OR 7 、-C(=O)NR 7 R 8 、-OC(=O)R 7 、-NC(=O)R 7 R 8 、-C(=O)R 7 、-S(=O)2OR 7 、-S(=O)2R 7 、-S(=O)2NR 7 R 8 、-OS(=O)2R 7 、-NS(=O)2R 7 R 8 、-S(=O)R 7 wherein the alkyl, alkenyl or alkynyl group is optionally substituted by one or more selected from halogen, -NO2, -CN, -OH, -SH, -NH2, =O, -COOH and C 1-6 Substitution of alkyl groups;

[0463] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 alkyl;

[0464] R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl-C 1-4 Alkyl, three-membered to seven-membered heterocyclic group, three-membered to seven-membered heterocyclic group-C 1-4 Alkyl, C6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, -OR Y1 、-SR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 、-S(=O)2OR Y1 、-S(=O)2R Y1 、-S(=O)2NR Y1 R Y2 、-S(=O)R Y1 wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from =O, =S, -OR Y3 、-SR Y3 、-NR Y3 R Y4 、-C(=O)R Y3 、-C(=O)OR Y3 and -C(=O)NR Y3 R Y4 Substituents substituted;

[0465] R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-8 Alkyl, -C 3-10 Cycloalkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl-C 1-4 Alkyl, three-membered to ten-membered heterocyclic group, three-membered to ten-membered heterocyclic group-C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl-C 1-4 alkyl, five-membered to ten-membered heteroaryl, five-membered to ten-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Substituents of alkynyl, -OH, -SH, -NH2, =O and -COOH.

[0466] <2> above <1> The use of wherein the B ring is a saturated or unsaturated six-membered heterocyclic ring; the heterocyclic ring contains 1 or 2 heteroatoms each independently selected from N and O.

[0467] <3> above <1> or <2> The use of a compound of claim 1, wherein ring B is dihydropyrimidine.

[0468] <4> above <1> or <2> The use of wherein the B ring is 2H-pyran or 4H-pyran; preferably 2H-pyran.

[0469] <5> above <1> to <4> The use of any one of the following, wherein R 1 =O.

[0470] <6> above <3> The use of wherein the AB ring system is

[0471] <7> above <4> The use of wherein the AB ring system is

[0472] <8> above <1> to <7> The use of any one of the above, wherein L 1 is a bond, or is a C1-C2 hydrocarbon chain.

[0473] <9> above <1> to <8> The use of any one of the following, wherein R 2 Selected from H, halogen, -NO2, -CN, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, -NO2, -CN, C 1-6 Alkyl and -NR a2 R b2 Preferably, R 2 Selected from H, halogen, C 1-6 Alkyl, wherein the alkyl is optionally substituted by one or more selected from halogen, C 1-6 Alkyl and -NR a2 R b2 More preferably, R 2 H or C 1-4 Alkyl, wherein the alkyl is optionally substituted by one or more selected from -NR a2 R b2 Particularly preferably, R 2 H or C 1-4 Alkyl, wherein the alkyl is -CH[CH(CH3)2]-, and is optionally substituted by one or more selected from -NR a2 R b2 substituted by a group.

[0474] <10> above <9> Uses, where R 2 For H.

[0475] <11> above <1> to <10> The use of any one of the following, wherein R X1 and R X2 Each occurrence is independently selected from halogen, C 1-6 Alkyl, -OR 7 、-NR 7 R 8 Preferably, R X1 and R X2 Each occurrence is independently selected from halogen, C 1-6 Alkyl, -OR 7 、-NR 7 R 8 More preferably, R X1 and R X2 is independently selected at each occurrence from halogen, -OR 7 ; Further preferably, R X1 and R X2 Each occurrence is independently selected from Cl, Br, -OH, -O(C 1-6 alkyl); particularly preferably, R X1 and R X2 is independently selected at each occurrence from Cl and -OH; wherein

[0476] R 7 、R 8 Each occurrence is independently selected from H, C 1-6 alkyl.

[0477] <12> above <1> to <11> The use of any one of the following, wherein R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)OR Y1 、-C(=O)NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally replaced by one or more selected from -OR Y3 and -NR Y3 R Y4 Preferably, R a1 、R b1 、R c1 、R a2 、R b2 、Rc2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally replaced by one or more selected from -OR Y3 and -NR Y3 R Y4 More preferably, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-6 Alkyl, -OR Y1 、-NR Y1 R Y2 、-C(=O)R Y1 wherein the alkyl group is optionally replaced by one or more selected from -NR Y3 R Y4 Particularly preferably, R a1 、R b1 、R c1 、R a2 、R b2 、R c2 Each occurrence is independently selected from H, C 1-3 Alkyl, -OH, p-methylbenzoyl; wherein the alkyl is optionally substituted by one or more groups selected from -NH2.

[0478] <13> above <1> to <12> The use of any one of the following, wherein R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-6 Alkyl, phenyl, phenyl-C 1-4 alkyl, five-membered to six-membered heteroaryl, five-membered to six-membered heteroaryl-C 1-4 Alkyl, wherein the alkyl or phenyl group is optionally substituted by one or more radicals selected from halogen, -NO2, -CN, -OH, -SH, -NH2, -COOH and C 1-6 The alkyl group is substituted with a substituent; preferably, R Y1 、R Y2 、R Y3 、R Y4 Each occurrence is independently selected from H, C 1-6 Alkyl, phenyl, phenyl-C 1-4Alkyl, wherein the alkyl or phenyl group is optionally substituted by one or more selected from halogen, C 1-6 The alkyl group is substituted; particularly preferably, R Y1 、R Y2 、R Y3 、R Y4 is independently selected at each occurrence from H and p-methylphenyl.

[0479] <14> above <1> to <13> The use of any one of the above, wherein the compound of formula (I') is selected from:

[0480]

[0481] <15> Use of a pharmaceutical composition in the preparation of a drug for preventing or treating PolyQ-related neurodegenerative diseases; the pharmaceutical composition comprises the above <1> to <14> The compound of formula (I') described in any one of the preceding claims, or a pharmaceutically acceptable salt, stereoisomer, solvate, polymorph, tautomer, isotope compound, metabolite or prodrug thereof, and at least one pharmaceutically acceptable carrier.

[0482] <16> above <1> to <15> The method of claim 1 , wherein the PolyQ-related neurodegenerative disease is selected from spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 7, spinocerebellar ataxia type 12, spinocerebellar ataxia type 17, dentate-nigral-rubral-pallidum-subthalamic atrophy, Huntington's disease and spinobulbar muscular atrophy, in particular Huntington's disease and spinocerebellar ataxia type 3.

[0483] Beneficial effects

[0484] The compounds of the present invention have the effect of reducing the levels of polyQ-GFP fusion proteins with longer polyQ residues in cells, but do not reduce the levels of polyQ-GFP fusion proteins with shorter polyQ residues. Therefore, the compounds of the present invention can reduce the levels of polyQ proteins with longer polyQ residues in cells or tissues, thereby having a preventive or therapeutic effect on polyQ protein-related diseases.

[0485] The inventors further discovered that the compounds of the present invention have an unexpected regulatory effect on mHTT levels in cells and have good safety. Administration of the compounds of the present invention can improve the survival rate and crawling ability of HD model fruit flies. Administration of the compounds of the present invention by intraventricular or intraperitoneal injection can reduce the mHTT levels in the cerebral cortex and striatum of HD model mice in an allele-selective manner without affecting the levels of wtHTT, which has important physiological functions, and improve the behavioral defects of mice. In neurons differentiated from HD patient-induced stem cells (iPSCs), the compounds of the present invention reduce mHTT levels, rescue disease-related phenotypes, and delay neuronal apoptosis. Therefore, the compounds of the present invention have good selectivity, therapeutic effects and safety, and are easy to pass through the BBB, which is conducive to oral administration.

[0486] In addition, the compound of the present invention can significantly reduce the level of mutant ATXN3 protein in cells, and thus can be used for the treatment or prevention of spinocerebellar ataxia type 3.

[0487] Therefore, the compound of the present invention can treat polyQ protein-related diseases, and has the advantages of high selectivity and good safety, as well as good prospects for development as an oral drug.

[0488] Example

[0489] Unless otherwise specified, all instruments and reagents used herein are commercially available.

[0490] In all statistical analyses, * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001; and **** indicates p < 0.0001. For comparisons between two groups, the statistical analysis method used was a two-tailed unpaired t-test. For comparisons between three or more groups, a two-tailed one-way analysis of variance was used when only one variable was influential, and a two-tailed two-way analysis of variance was used when two variables were influential.

[0491] abbreviation

[0492]

[0493] Experimental materials, reagents, and procedures

[0494] Compound

[0495] Compound 1: ispinesib, PubChem CID: 6851740, available from Selleck, catalog number S1452;

[0496] Compound 2: PubChem CID 5398649, available from ChemDiv, catalog number D715-2435;

[0497] Compound 3: Semaxanib, available from Selleck, CAS No. 194413-58-6;

[0498] Compound 4: Su9516, available from Selleck, CAS No. 377090-84-1;

[0499] Compound 5: can be purchased from Sinopharm Chemical Reagent Co., Ltd., CAS No. 779-30-6;

[0500] Compound 6: can be purchased from TargetMol, CAS No. 842-01-3;

[0501] Compound 7: can be purchased from ChemDiv.

[0502] Antibody

[0503] The antibodies used for western blotting, HTRF and / or immunofluorescence / immunohistochemistry are as follows: HTT antibodies 2B7 (Weiss et al. Anal Biochem 2009, 395, 8-15), 4C9, ab1 (Sapp et al. J Biol Chem 2012, 287, 13487-13499) and MW1 (Ko et al. Brain research bulletin 2001, 56, 319-329) were prepared using existing methods; the antibody S830 used for immunostaining to detect HTT aggregates was donated by Dr. Gillian Bates; other antibodies were purchased from Millipore, Sigma and other companies.

[0504] Preparation and verification of recombinant human full-length HTT protein

[0505] (1) With (CAG) 23 or (CAG) 73 The human HTT gene (GenBank: NM_002111.8) was synthesized de novo by Genewiz Inc. The human HTT gene was cloned into a modified pCAG vector (from Addgene) with an N-terminal protein A tag.

[0506] (2) The plasmid was transfected into human embryonic kidney E293 cells using polyethyleneimine (PEI, from Polysciences, 23966) for expression. The protein was purified using IgG monoclonal antibody-agarose (Smart-lifesciences, SA030010). The protein A tag was removed by TEV protease digestion, and the protein was further purified using Mono Q and Superose 6 (5 / 150 GL) columns from GE Healthcare. The protein was verified by Coomassie blue staining and Western blotting.

[0507] Cells used for experiments

[0508] Primary cultured cortical neurons: Hdh Q140 / Q7 and Hdh Q7 / Q7 The brains of newborn mice (P0) were dissected, digested, dissociated, and then cultured.

[0509] Primary patient fibroblasts and wild-type cells were obtained from Huntington's disease (HD) patients (Q47, Q55) and healthy controls (WT, Q19) from a Mongolian Huntington's disease family. The SCA3 cell line was obtained from a patient (Q74). The HD Q68 fibroblast cell line was obtained from Coriell Cell Repositories (Camden, NJ, USA). Immortalized fibroblasts and iPS cells (iPSCs) were generated from primary fibroblasts. HEK293T cells were obtained from ATCC.

[0510] Animals used in experiments

[0511] Huntington's disease fruit flies

[0512] The nervous system driver line elav-GAL4(c155) and the HTT-expressing lines UAS-fl-HTT-Q16 and UAS-fl-HTT-Q128 were obtained from the Bloomington Drosophila Stock Center of Indiana University (http: / / flystocks.bio.indiana.edu / ) and maintained in a 25°C incubator.

[0513] By crossing elav-GAL4 virgin flies with UAS-fl-HTT-Q16 or UAS-fl-HTT-Q128 male flies, transgenic flies expressing human HTT full-length protein (Q16) or (Q128) driven by elav-GAL4 in the nervous system were obtained.

[0514] Huntington's disease mice

[0515] Mice expressing wild-type HTT gene (Hdh Q7 / Q7), from the laboratory of Marian Difiglia, Massachusetts General Hospital, Harvard University. Q140 gene knock-in heterozygous mice (Hdh) were prepared according to the existing technology (Menalled et al., J Comp Neurol, 2003, 465: 11-26). Q140 / Q7 ).

[0516] Protein analysis

[0517] Homogeneous time-resolved fluorescence (HTRF) analysis: the original lysis buffer PBS + 1% (v / v) Triton X-100 + 1× cOmplete TM Cell or tissue lysates were diluted with protease inhibitors, lysed, and probed with the indicated antibody pairs diluted in HTRF assay buffer (50 mM NaH2PO4, 400 mM NaF, 0.1% BSA, 0.05% (v / v) Tween-20, 1% (v / v) Triton X-100, pH 7.4). The donor antibody concentration in HTRF buffer was 0.023 ng / μL, and the acceptor antibody concentration was 1.4 ng / μL.

[0518] Protein Amount Determination: Determine protein amount as described above. Perform background correction using a blank sample. Determine protein concentration for all samples to correct for protein amount. Test each well for different protein concentrations or cell numbers to ensure the signal is within the linear range.

[0519] Cell analysis

[0520] Immunofluorescence: Cells were washed, fixed, permeabilized, and blocked, then incubated with primary antibodies overnight at 4°C, washed three times with blocking buffer, and incubated with secondary antibodies for 1 hour at room temperature. They were stained with DAPI, mounted, and imaged using a Zeiss Axio Vert A1 confocal microscope. TUBB3 or colocalization was analyzed using ImageJ.

[0521] Example 1 Effects of Compounds on Protein Levels Containing Longer Glutamine Repeat Regions

[0522] The inventors used HEK293T cells exogenously expressing polyQ-GFP fusion proteins (Q72-GFP or Q25-GFP) to detect compounds that could control the levels of proteins containing long glutamine repeat regions in cells. The method is as follows:

[0523] (1) A polyQ-GFP cDNA sequence (expressing Met-polyQ-GFP, where polyQ is Q72 or Q25) was synthesized de novo and subcloned into a pcDNA vector. This cDNA was forward transfected into HEK293T cells (ATCC, CRL-3216) to obtain cells expressing Q72-GFP and Q25-GFP, respectively. Furthermore, cells expressing Q53-GFP, Q46-GFP, and Q38-GFP were obtained using the same method.

[0524] (2) Purifying the polyQ-GFP proteins expressed by (1) to obtain Q72-GFP, Q53-GFP, Q46-GFP, Q38-GFP, and Q25-GFP (SEQ ID NO: 1). The difference between the amino acid sequences of Q72-GFP, Q53-GFP, Q46-GFP, and Q38-GFP and those of SEQ ID NO: 1 lies in the length of the glutamine repeat region.

[0525] (3) Using the Q72-GFP expressing cells and Q25-GFP expressing cells obtained in step (1), the cells were treated with 100 nM of compound 1 or 50 nM of compound 2, and the polyQ-GFP level was measured by fluorescence counting using Incucyte assay after 2 days. Figure 1 ). It was observed that Compound 1 and Compound 2 were able to effectively reduce the level of a protein containing a longer glutamine repeat region (Q72-GFP) in HEK293T cells, but did not reduce the level of a protein containing a shorter glutamine repeat region (Q25-GFP). This result indicates that the compounds of the present invention can selectively reduce the level of abnormally expanded polyQ proteins in cells.

[0526] Example 2 Effects of Compounds on Proteins Containing Longer Glutamine Repeat Regions

[0527] 2.1 OI-RD assay for affinity activity of compounds to proteins containing long glutamine repeat regions

[0528] A contact microarray printer (SmartArrayer 136, CapitalBio Corporation) was used to prepare compound chips according to the existing technology (Zhu et al., Sensors (Basel) 2016, 16(3), 378; Fei et al., J Biomed Opt 2010, 15(1), 016018). Each compound was printed in triplicate. The affinity reaction parameters of the compound with GFP or the polyQ-GFP protein obtained in step (2) of Example 1 were measured using OI-RD. The compound did not have affinity binding with Q25-GFP or GFP, but was able to bind to proteins with longer glutamine repeat regions. For example, compound 2 had a certain affinity binding with proteins with 38 or more glutamine repeats, and the affinity reaction parameters are shown in Table 1.

[0529] Table 1. Association rate constants, dissociation rate constants, and equilibrium dissociation constants of compound 2 for affinity reactions with Q72-GFP, Q53-GFP, Q46-GFP, and Q38-GFP

[0530] <![CDATA[K on (min·nM) -1 ]]> <![CDATA[K off (min) -1 ]]> <![CDATA[K d (nM)]]> Q72-GFP <![CDATA[6.20×10 -5 ]]> <![CDATA[1.92×10 -2 ]]> 309.7 Q53-GFP <![CDATA[1.08×10 -4 ]]> <![CDATA[4.65×10 -3 ]]> 43.1 Q46-GFP <![CDATA[7.65×10 -6 ]]> <![CDATA[2.57×10 -2 ]]> 3359.5 Q38-GFP <![CDATA[2.99×10 -6 ]]> <![CDATA[1.5×10 -2 ]]> 5016.7

[0531] 2.2 MST assay of the affinity activity of compounds to proteins containing long glutamine repeat regions

[0532] Furthermore, the affinity activity of compound 2 for proteins containing long glutamine repeat regions was tested using a microthermophoresis instrument (MST, where the Monolith NT.115 instrument was from NanoTemper Technologies). The reaction buffer was 20mM HEPES, pH 7.4, 150mM NaCl, and the protein concentration was 500nM. Compound 2 had no affinity binding to Q25-GFP, but had a K of 0.05 for Q72-GFP. d 2.80μM.

[0533] In summary, the results of both OI-RD and MST assays indicate that the compounds of the present invention selectively bind to proteins containing a longer glutamine repeat region.

[0534] Example 3 Effects of Compounds on Full-Length mHTT

[0535] 3.1 OI-RD assay of the affinity of compounds to full-length HTT

[0536] A contact microarray printer (SmartArrayer 136, CapitalBio Corporation) was used to prepare compound chips according to the prior art (Zhu et al., Sensors (Basel) 2016, 16(3), 378; Fei et al., J Biomed Opt 2010, 15(1), 016018). Each compound was printed in triplicate. OI-RD was used to measure the affinity reaction parameters of the compound with full-length mHTT (flHTT-Q73) and full-length HTT-Q23 (flHTT-Q23, SEQ ID NO: 2) ( Figure 2 The compound had no affinity binding to fl-HTT-Q23, and the association rate constant, dissociation rate constant, and equilibrium dissociation constant of the affinity reaction with flHTT-Q73 are shown in Table 2.

[0537] Table 2. Association rate constants, dissociation rate constants, and equilibrium dissociation constants of the affinity reactions of the compounds with flHTT-Q73

[0538]

[0539] 3.2 MST assay of the affinity activity of compounds to full-length HTT

[0540] The affinity of the compound to full-length HTT was verified using a microthermophoresis instrument (MST, where the Monolith NT.115 instrument was from NanoTemper Technologies). Figure 3 The reaction buffer was 20 mM HEPES, pH 7.4, 150 mM NaCl, and the protein concentration was 500 nM. The compound of the present invention had no affinity binding to fl-HTT-Q23. The K d The K of compound 2 and flHTT-Q73 was 0.13 μM. d It is 2.82μM.

[0541] In summary, both OI-RD and MST assay results demonstrate that the compounds of the present invention selectively bind to flHTT-Q73. This conclusion is consistent with the finding that the compounds selectively reduce the levels of proteins containing long glutamine repeat regions in HEK293T cells, suggesting that the compounds' effects on these proteins may be achieved through selective binding to proteins containing long glutamine repeat regions.

[0542] Example 4 Effects of the Compound on Cortical Neurons of HD Model Mice

[0543] 4.1 Effects on mHTT and wtHTT Levels

[0544] (1) Treating primary cultured Hdh with compounds Q140 / Q7 and Hdh Q7 / Q7 Mouse cortical neuronal cells, after 2 days, the levels of mHTT and wtHTT were detected by Western blotting (2166 antibody) ( Figure 4 and Figure 5 Compounds 1 and 2 can induce Q140 gene knock-in heterozygous mice (Hdh Q140 / Q7 ) The mHTT level in cortical neurons was reduced, while wtHTT level was barely affected. Compound 1 did not reduce Hdh Q7 / Q7 wtHTT levels in mouse cortical neurons.

[0545] (2) mHTT was detected using anti-polyQ antibodies MW1 and 3B5H10, and the bands of proteins with smaller molecular weight were observed. No increase in the N-terminal fragments of mHTT was observed ( Figure 6 The detected decrease in mHTT levels was not due to an increase in site-specific splicing.

[0546] 4.2 Cytotoxicity test

[0547] Hdh treated with the indicated compounds was measured by CellTiter-glo (Promega, catalog number G7570) according to the protocol provided in the kit. Q140 / Q7 Viability of mouse cortical neurons ( Figure 7 ).

[0548] The compounds of the present invention have an effect on Hdh at the test concentrations described in 4.1. Q140 / Q7 There was no cytotoxicity in mouse cortical neurons. The detected decrease in mHTT levels was not due to neuronal cell loss.

[0549] In summary, the compounds of the present invention can allele-selectively reduce mHTT levels in cells, have no cytotoxicity, and have good safety.

[0550] Example 5 Effects of Compounds on mHTT and wtHTT Levels in Fibroblasts from Huntington's Disease Patients

[0551] 5.1 Effects on mHTT and wtHTT Levels in Primary Fibroblasts from HD Patients

[0552] Preliminary experiments were performed to determine that the compound exhibited the best effect of reducing mHTT levels at a concentration of 100 nM.

[0553] Experimental method: HD patient fibroblasts (Q49, Q55, Q68) were treated with 100 nM concentration of compound, and mHTT (antibody pair: 2B7 / MW1) and total HTT (antibody pair: 2B7 / 2166) were detected by HTRF 2 days later. The results are as follows: Figure 8 As shown in Figure 2, reduced mHTT levels were observed in primary fibroblasts from HD patients (Q49, Q55, and Q68). No reduction in HTT levels was observed in wild-type primary fibroblasts.

[0554] 5.2 Effects on mHTT Levels in Immortalized Fibroblasts from HD Patients

[0555] The effect of the compounds of the present invention on the mHTT level of immortalized HD patient fibroblasts was detected by HTRF (antibody pair: 2B7 / MW1) using a similar experimental method as described in 5.1. Figure 9 ). Reduced mHTT levels were observed in immortalized HD patient fibroblasts. Figure 10 Compound 2 is shown to reduce mHTT levels in immortalized HD patient fibroblasts at different doses.

[0556] Example 6 Effects of Compounds on mHTT Levels and Neuronal Apoptosis Induced by Stem Cell Differentiation in HD Patients

[0557] 6.1 Effects on mHTT and wtHTT Levels

[0558] Experimental Materials:

[0559] The effects of Compound 1 and Compound 2 on the mHTT level of neurons (Q47) differentiated from HD patient induced stem cells (iPSCs) were detected by HTRF (antibody pair: 2B7 / MW1) using a similar experimental method as described in 5.1. Figure 11 ). Reduced mHTT levels were observed in neuronal cells differentiated from HD patient induced stem cells (iPSCs). Using the same method, it was observed that compounds 3, 4, 5, 6, and 7 reduced mHTT levels in neuronal cells differentiated from HD patient induced stem cells (iPSCs). Compound 3 reduced mHTT levels by approximately 12.2%, compound 4 reduced mHTT levels by approximately 24.9%, compound 5 reduced mHTT levels by approximately 26.8%, compound 6 reduced mHTT levels by approximately 24.2%, and compound 7 reduced mHTT levels by approximately 19.7%.

[0560] The compounds of the present invention rescue disease-associated phenotypes in neuronal cells differentiated from induced PS cells (iPSCs) derived from HD patients.

[0561] 6.2 Effects on Neuronal Apoptosis

[0562] (1) Immunostaining

[0563] Neurons (Q47) differentiated from HD patient induced pluripotent stem cells (iPSCs) were treated with 100 nM Compound 1 or 50 nM Compound 2. The cells were stressed (BDNF depletion) 1 day after compound treatment.

[0564] The neuron-specific tubulin marker TUBB3 was stained with DAPI. The TUBB3 signal coverage area was normalized by cell nucleus count and the data were normalized to the wild type as the control to analyze neuronal apoptosis ( Figure 12 ).

[0565] (2) Caspase-3 activity detection

[0566] After depletion of BDNF, HD neurons were observed to arrest and experience neuronal shrinkage.

[0567] Active caspase-3 was detected using NucView 488 (Biotium, 30029). After BDNF removal, images were captured every 3 hours in the incubator using Incucyte (Essen Bioscience, IncuCyte FLR) and analyzed using Incucyte 2011A software. Three batches were tested and the results were consistent ( Figure 13 Compounds 1 and 2 significantly improved the arrest of progression and neuronal shrinkage in HD neurons after BDNF removal.

[0568] Example 7 Effects of the Compound on Huntington's Disease Drosophila

[0569] 7.1 Effects on mHTT Levels

[0570] Experimental methods:

[0571] Q128 fruit flies and Q16 fruit flies were randomly divided into a negative control group and a positive drug group (Compound 1, Compound 2), with 75 flies in each group. The negative control group was administered with the corresponding solvent DMSO, and the positive drug group was administered with the corresponding positive drug.

[0572] Flies were maintained on standard diet at 25° C. Newly hatched flies were transferred to assigned vials containing either positive drug (10 μM in 400 μL DMSO) or DMSO for control, and the corn diet was changed every other day.

[0573] Feed continuously for 6 days. On the 7th day, extract the protein of Drosophila head and measure the mHTT level by HTRF (antibody pair: 2B7 / MW1), where each sample includes protein extracted from 5 Drosophila heads ( Figure 14 Compounds 1 and 2 reduced the mHTT level in transgenic Drosophila expressing the full-length human HTT protein (Q128).

[0574] 7.2 Effects of Compounds on Survival

[0575] Seventy-five age-matched virgin flies were placed into empty plastic vials containing standard food, and the survival of each vial was recorded daily to measure lifespan ( Figure 15 The survival rate of the Q128-positive fruit fly group was improved compared with the control group.

[0576] 7.3 Impact on crawling ability

[0577] Fifteen age-matched virgin flies were placed in an empty bottle and tapped to rest on the bottom. The percentage of flies that climbed over a 7-cm height after 15 seconds was recorded. The average of five observations was recorded for each vial daily, and data from multiple vials containing different batches of flies were recorded and analyzed.

[0578] The results are as follows Figure 16 The numbers in the brackets indicate the number of vials tested. The crawling ability of the Q128-positive Drosophila group was improved relative to that of the control group.

[0579] In the tests described in 7.2 and 7.3 above, no effects of the compounds on Q16 flies were observed.

[0580] Example 8 Effects of Compounds on HD Model Mice

[0581] Experimental Animals: Mice were group-housed in individually ventilated cages with a 12-h light / dark cycle, with a maximum of 5 adult mice per cage.

[0582] 8.1 Effects of intracerebroventricular injection of compounds on mHTT and wtHTT levels in the cortex of HD mice

[0583] Experimental animals: Hdh Q140 / Q7 Mice (3 months old), 4 per group;

[0584] Experimental method: 2 μL of artificial cerebrospinal fluid (ACSF: 1 mM glucose, 119 mM NaCl, 2.5 mM KCl, 1.3 mM MgSO4, 2.5 mM CaCl2, 26.2 mM NaHCO3, 1 mM NaH2PO4) containing the compound at a concentration of 25 μM was administered intracerebroventricularly once daily. 2 μL of ACSF containing an equal amount of DMSO was used as a control.

[0585] Ten days after injection, the mouse cerebral cortex neuronal proteins were extracted and the mHTT and wtHTT levels were detected by Western blotting (2166 antibody). Each sample was tested three times and the average value was calculated ( Figure 17 Compound 2 significantly reduced the level of mHTT in the cortex of HdhQ140 / Q7 mice and showed mHTT selectivity relative to wtHTT.

[0586] 8.2 Intraperitoneal injection of compound 2

[0587] Experimental method: DMSO for compound or control was diluted to 0.05 μg / μL with 0.9% NaCl intravenous infusion solution and injected intraperitoneally once a day (0.5 mg / kg). Tissue extraction or behavioral experiments were performed 14 days after injection.

[0588] In vivo compound detection in mouse brain tissue following intraperitoneal injection: Two hours after intraperitoneal administration of DMSO or compound, brains were dissected and weighed, and compound extraction was performed. LC-MS / MS analysis was performed using UPLC-MS (Acquity Ultra Performance Liquid Chromatography System, Acquity UPLC BEH C18 (1.7 μm, 2.1 × 50 mm) column, and Xevo TQ-S mass spectrometer, Waters Corporation, Milford, MA, USA). The level of compound 2 reaching brain tissue was 9.48 ng / g. No compound mass spectrometry signal was observed in the control (DMSO) group. The compounds of the present invention were successfully delivered to the mouse brain across the BBB, facilitating oral administration of compounds.

[0589] 8.3 Effects of intraperitoneal injection of compounds on mHTT and wtHTT levels in the cortex and striatum of HD mice

[0590] (1) Take Hdh Q140 / Q7 Mice (5 months old), a total of 13, were divided into 2 groups

[0591] Compound 2 was administered according to the steps described in 8.2. The compound was intraperitoneally injected once a day. After 14 days of injection, the protein was extracted and the levels of mHTT and wtHTT in the cortex of HD mice were detected by Western blotting ( Figure 18 ).

[0592] (2) Take Hdh Q140 / Q7 There were 13 mice (10 months old), with 6-7 mice in each group.

[0593] The above method was used to administer the drug and extract the neuronal proteins in the striatum of the mouse brain, and the levels of mHTT and wtHTT were detected by Western blotting ( Figure 19 ).

[0594] (3) Detection of Hdh by dot-blot assay (antibody: 4C9, bar graph shows results of two replicates) and HTRF (antibody pair: 4C9 / 4C9) Q140 / Q7 mHTT aggregates in mouse cortex. Each mouse was sampled two to three times on average ( Figure 20 No increase in mHTT aggregates was observed. The decrease in mHTT levels in the Compound 2-treated group was not due to changes in mHTT solubility.

[0595] In summary, intraperitoneal administration of compound 2 reduced mHTT levels in the cortex and striatum of HdhQ140 / Q7 mice and exhibited mHTT selectivity relative to wtHTT. Therefore, compound 2 has the potential to be developed as an oral drug.

[0596] 8.4 Effects of intraperitoneal injection of compound 2 on behavioral deficits in HD mice

[0597] Experimental animals: Hdh Q140 / Q7 Mice, a total of 32, were divided into 2 groups; (Hdh Q7 / Q7 ) mice, a total of 28, were divided into 2 groups

[0598] Experimental method: Compound 2 was administered according to the procedure described in 8.2. It was intraperitoneally injected once a day. Behavioral experiments were performed 14 days after the injection.

[0599] All behavioral experiments were performed during the light phase. All mice were kept in the behavioral testing room under dim red light for one hour before the start of the experiment.

[0600] All behavioral experiments were performed during the light phase. All mice were kept in the behavioral testing room under dim red light for one hour before the start of the experiment.

[0601] Rotarod test: Mice were pretrained (rotating on the rotarod at 4 rpm for 2 minutes) for 3 consecutive days. Mice were then tested for 5 days at an accelerating speed of 4 to 40 rpm within 2 minutes. The results of each experiment were recorded as the time on the rod (time on the rotarod) until falling from the rod or until the task was completed. Each test consisted of three repetitions with a 60-minute interval between trials to reduce stress and fatigue. The average of three trials for each mouse was analyzed ( Figure 21 a).

[0602] Balance beam test: A 2 cm thick, 100 cm long, graduated rod was suspended on both sides of a platform. There was a bright light at the starting point and a dark box containing food at the end point. The total time each mouse took to walk across the balance beam was recorded ( Figure 21 b) The compounds of the present invention can improve Huntington's disease-related behavioral deficits in HD model mice and have no effect on wild-type mice.

[0603] Example 9 Effects of Compounds on ATXN3 Protein with Abnormal PolyQ Expansion

[0604] 9.1 Preparation of recombinant human MBP-ATXN3

[0605] (1) A His8 tag and a TEV protease cleavage site were added to the pMal-C2x plasmid (from New England Biolabs) to prepare the prokaryotic expression vector pMBP. The ATXN3 gene (GenBank: NM_001127696.2) was edited to control the length of the glutamine repeat region, amplified, and cloned into the prepared pMBP vector to obtain the pMBP-ATXN3-Q28 and pMBP-ATXN3-Q68 plasmids containing 28 and 68 polyQ repeats, respectively.

[0606] (2) The expression plasmids pMBP-ATXN3-Q28 and pMBP-ATXN3-Q68 were introduced into Escherichia coli Rosetta (DE3) pLsyS for expression and initially purified using a HisTrap HP column (GE Healthcare, 17524701). The product was concentrated by ultrafiltration and then further purified using a Superose 6Increase 10 / 300GL size exclusion column (GE Healthcare).

[0607] (3) SDS-PAGE verification showed that the purity of the prepared human MBP-ATXN3-Q28 and MBP-ATXN3-Q68 exceeded 98%.

[0608] 9.2 MST Detection of Compound Affinity for ATXN3 Protein with Abnormal PolyQ Expansion

[0609] According to the method in 2.2, the affinity activity of compound 2 with MBP-ATXN3-Q28 and MBP-ATXN3-Q68 proteins was verified by microthermophoresis.

[0610] The results showed that compound 2 had no affinity binding to the normal ATXN3 protein (MBP-ATXN3-Q28) and had a K d The compound of the present invention selectively and affinity binds to the ATXN3 protein with abnormal polyQ expansion.

[0611] Example 10 Effect of the compound on the ATXN3 protein level in fibroblasts from patients with spinocerebellar ataxia type 3

[0612] SCA3 patient fibroblasts (Q74) and wild-type cells (Q27) were treated with 100 nM of compound 1 or 50 nM of compound 2, and the levels of variant ATXN3 protein (ATXN3-Q74, SEQ ID NO: 3) and wild-type ATXN3 protein (ATXN3-Q27, SEQ ID NO: 4) were determined by Western blotting 2 days later. Figure 22A reduction in the level of mutant ATXN3 protein was observed in SCA3 patient fibroblasts (Q74), while a reduction in the level of wild-type ATXN3 protein was not observed. Therefore, the compound can be used to treat SCA3.

[0613] Effects of Example 11 Compounds on the Level of ATXN1 Protein in Cells with Abnormal PolyQ Expansion

[0614] (1) PolyQ-ATXN1 cDNA (wherein polyQ is Q92) was synthesized de novo and subcloned into a pcDNA vector. This cDNA was then transfected into HEK293T cells (ATCC, CRL-3216) to obtain cells expressing His-ATXN1-Q92.

[0615] (2) The cells prepared in (1) were treated with 100 nM of a compound (compound 1, or compound 2, or compound 4, or compound 6), and the level of the mutant ATXN1 protein (His-ATXN1-Q92, SEQ ID NO: 5 with a His tag at the N-terminus) was detected by HTRF 2 days later (antibody pair: anti-His-Tb / MW1-D2, Figure 23 Reduced levels of mutant ATXN1 protein were observed in fibroblasts (Q92) from SCA1 patients. Therefore, the compounds of the present invention can be used to treat or prevent spinocerebellar ataxia type 1.

[0616] Sequence Listing

[0617] [SEQ ID NO:1]Q25-GFP:

[0618] MQQQQQQQQQQQQQQQQQQQQQQQMSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDDG TYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHNVYITADKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSVLSKDPNEKRDHMVLLEFVTAAGITHGGSG

[0619] [SEQ ID NO: 2] HTT-Q23:

[0620]

[0621] [SEQ ID NO:3]ATXN3-Q74:

[0622] MESIFHEKQEGSLCAQHCLNNLLQGEYFSPVELSSIAHQLDEEERMRMAEGGVTSEDYRTFLQQPSGNMDDSGFFSIQVISNALKVWGLELILFNSPEYQRLRIDPINERSFICNYKEHWFTVRKLGKQWFNLNSLLTGPELISDTYLALFLAQLQQEGYSIFVVKGDLPDCEADQLLQMIRVQQMHRPKLIGEELAQLKEQRVHKTDLERMLEANDGSGMLDEDEEDLQRALALSRQEIDMEDEEADLRRAIQLSMQGSSRNISQDMTQTSGTNLTSEELRKRREAYFEKQQQKQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQRDLSGQSSHPCERPATSSGALGSDLGKACSPFIMFATFTLYLT

[0623] [SEQ ID NO:4]ATXN3-Q27:

[0624] MESIFHEKQEGSLCAQHCLNNLLQGEYFSPVELSSIAHQLDEEERMRMAEGGVTSEDYRTFLQQPSGNMDDSGFFSIQVISNALKVWGLELILFNSPEYQRLRIDPINERSFICNYKEHWFTVRKLGKQWFNLNSLLTGPELISDTYLALFLAQLQQEGYSIFVVKGDLPDCEADQLLQMIRVQQMHRPKLIGEELAQLKEQRVHKTDLERMLEANDGSGMLDEDEEDLQRALALSRQEIDMEDEEADLRRAIQLSMQGSSRNISQDMTQTSGTNLTSEELRKRREAYFEKQQQKQQQQQQQQQQQQQQQQQQQQQQQQQQQRDLSGQSSHPCERPATSSGALGSDLGKACSPFIMFATFTLYLT

[0625] [SEQ ID NO:5]ATXN1-Q92:

[0626] MKSNQERSNECLPPKKREIPATSRSSEEKAPTLPSDNHRVEGTAWLPGNPGGRGHGGGRHGPAGTSVELGLQQGIGLHKALSTGLDYSPPSAPRSVPVATTLPAAYATPQPGTPVSPVQYAHLPHTFQFIGSSQYSGTYASFIPSQLIPPTANPVTSAVASAAGATTPSQRSQLEAYSTLLANMGSLSQTPGHKAEQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQHQHQQQQQQQQQQQQQQHLSRAPGLITPGSPPPAQQNQYVHISSSPQNTGRTASPPAIPVHLHPHQTMIPHTLTLGPPSQVVMQYADSGSHFVPREATKKAESSRLQQAIQAKEVLNGEMEKSRRYGAPSSADLGLGKAGGKSVPHPYESRHVVVHPSPSDYSSRDPSGVRASVMVLPNSNTPAADLEVQQATHREASPSTLNDKSGLHLGKPGHRSYALSPHTVIQTTHSASEPLPVGLPATAFYAGTQPPVIGYLSGQQQAITYAGSLPQHLVIPGTQPLLIPVGSTDMEASGAAPAIVTSSPQFAAVPHTFVTTALPKSENFNPEALVTQAAYPAMVQAQIHLPVVQSVASPAAAPPTLPPYFMKGSIIQLANGELKKVEDLKTEDFIQSAEISNDLKIDSSTVERIEDSHSPGVAVIQFAVGEHRAQVSVEVLVEYPFFVFGQGWSSCCPERTSQLFDLPCSKLSVGDVCISLTLKNLKNGSVKKGQPVDPASVLLKHSKADGLAGSRHRYAEQENGINQGSAQMLSENGELKFPEKMGLPAAPFLTKIEPSKPAATRKRRWSAPESRKLEKSEDEPPLTLPKPSLIPQEVKICIEGRSNVGK Sequence Listing <110> Fudan University <120> Compound for Treating Neurodegenerative Diseases <130> P2019TC975 <160> 5 <170> PatentIn version 3.5 <210> 1 <211> 261 <212> PRT <213> Homo sapiens <220> <223> Q25-GFP <400> 1 Met Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 1 5 10 15 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Met Ser Lys Gly Glu Glu 20 25 30 Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu Leu Asp Gly Asp Val 35 40 45 Asn Gly His Lys Phe Ser Val Arg Gly Glu Gly Glu Gly Asp Ala Thr 50 55 60 Asn Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr Gly Lys Leu Pro 65 70 75 80 Val Pro Trp Pro Thr Leu Val Thr Thr Leu Thr Tyr Gly Val Gln Cys 85 90 95 Phe Ser Arg Tyr Pro Asp His Met Lys Arg His Asp Phe Phe Lys Ser 100 105 110 Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Ser Phe Lys Asp 115 120 125 Asp Gly Thr Tyr Lys Thr Arg Ala Glu Val Lys Phe Glu Gly Asp Thr 130 135 140 Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp Phe Lys Glu Asp Gly 145 150 155 160 Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Phe Asn Ser His Asn Val 165 170 175 Tyr Ile Thr Ala Asp Lys Gln Lys Asn Gly Ile Lys Ala Asn Phe Lys 180 185 190 Ile Arg His Asn Val Glu Asp Gly Ser Val Gln Leu Ala Asp His Tyr 195 200 205 Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu Pro Asp Asn 210 215 220 His Tyr Leu Ser Thr Gln Ser Val Leu Ser Lys Asp Pro Asn Glu Lys 225 230 235 240 Arg Asp His Met Val Leu Leu Glu Phe Val Thr Ala Ala Gly Ile Thr 245 250 255 His Gly Gly Ser Gly 260 <210> 2 <211> 3144 <212> PRT <213> Homo sapiens <220> <223> HTT-Q23 <400> 2 Met Ala Thr Leu Glu Lys Leu Met Lys Ala Phe Glu Ser Leu Lys Ser 1 5 10 15 Phe Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 20 25 30 Gln Gln Gln Gln Gln Gln Gln Gln Pro Pro Pro Pro Pro Pro Pro Pro 35 40 45 Pro Pro Pro Gln Leu Pro Gln Pro Pro Pro Gln Ala Gln Pro Leu Leu 50 55 60 Pro Gln Pro Gln Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Gly Pro 65 70 75 80 Ala Val Ala Glu Glu Pro Leu His Arg Pro Lys Lys Glu Leu Ser Ala 85 90 95 Thr Lys Lys Asp Arg Val Asn His Cys Leu Thr Ile Cys Glu Asn Ile 100 105 110 Val Ala Gln Ser Val Arg Asn Ser Pro Glu Phe Gln Lys Leu Leu Gly 115 120 125 Ile Ala Met Glu Leu Phe Leu Leu Cys Ser Asp Asp Ala Glu Ser Asp 130 135 140 Val Arg Met Val Ala Asp Glu Cys Leu Asn Lys Val Ile Lys Ala Leu 145 150 155 160 Met Asp Ser Asn Leu Pro Arg Leu Gln Leu Glu Leu Tyr Lys Glu Ile 165 170 175 Lys Lys Asn Gly Ala Pro Arg Ser Leu Arg Ala Ala Leu Trp Arg Phe 180 185 190 Ala Glu Leu Ala His Leu Val Arg Pro Gln Lys Cys Arg Pro Tyr Leu 195 200 205 Val Asn Leu Leu Pro Cys Leu Thr Arg Thr Ser Lys Arg Pro Glu Glu 210 215 220 Ser Val Gln Glu Thr Leu Ala Ala Ala Val Pro Lys Ile Met Ala Ser 225 230 235 240 Phe Gly Asn Phe Ala Asn Asp Asn Glu Ile Lys Val Leu Leu Lys Ala 245 250 255 Phe Ile Ala Asn Leu Lys Ser Ser Ser Pro Thr Ile Arg Arg Thr Ala 260 265 270 Ala Gly Ser Ala Val Ser Ile Cys Gln His Ser Arg Arg Thr Gln Tyr 275 280 285 Phe Tyr Ser Trp Leu Leu Asn Val Leu Leu Gly Leu Leu Val Pro Val 290 295 300 Glu Asp Glu His Ser Thr Leu Leu Ile Leu Gly Val Leu Leu Thr Leu 305 310 315 320 Arg Tyr Leu Val Pro Leu Leu Gln Gln Gln Val Lys Asp Thr Ser Leu 325 330 335 Lys Gly Ser Phe Gly Val Thr Arg Lys Glu Met Glu Val Ser Pro Ser 340 345 350 Ala Glu Gln Leu Val Gln Val Tyr Glu Leu Thr Leu His His Thr Gln 355 360 365 His Gln Asp His Asn Val Val Thr Gly Ala Leu Glu Leu Leu Gln Gln 370 375 380 Leu Phe Arg Thr Pro Pro Pro Glu Leu Leu Gln Thr Leu Thr Ala Val 385 390 395 400 Gly Gly Ile Gly Gln Leu Thr Ala Ala Lys Glu Glu Ser Gly Gly Arg 405 410 415 Ser Arg Ser Gly Ser Ile Val Glu Leu Ile Ala Gly Gly Gly Ser Ser 420 425 430 Cys Ser Pro Val Leu Ser Arg Lys Gln Lys Gly Lys Val Leu Leu Gly 435 440 445 Glu Glu Glu Ala Leu Glu Asp Asp Ser Glu Ser Arg Ser Asp Val Ser 450 455 460 Ser Ser Ala Leu Thr Ala Ser Val Lys Asp Glu Ile Ser Gly Glu Leu 465 470 475 480 Ala Ala Ser Ser Gly Val Ser Thr Pro Gly Ser Ala Gly His Asp Ile 485 490 495 Ile Thr Glu Gln Pro Arg Ser Gln His Thr Leu Gln Ala Asp Ser Val 500 505 510 Asp Leu Ala Ser Cys Asp Leu Thr Ser Ser Ala Thr Asp Gly Asp Glu 515 520 525 Glu Asp Ile Leu Ser His Ser Ser Ser Gln Val Ser Ala Val Pro Ser 530 535 540 Asp Pro Ala Met Asp Leu Asn Asp Gly Thr Gln Ala Ser Ser Pro Ile 545 550 555 560 Ser Asp Ser Ser Gln Thr Thr Thr Glu Gly Pro Asp Ser Ala Val Thr 565 570 575 Pro Ser Asp Ser Ser Glu Ile Val Leu Asp Gly Thr Asp Asn Gln Tyr 580 585 590 Leu Gly Leu Gln Ile Gly Gln Pro Gln Asp Glu Asp Glu Glu Ala Thr 595 600 605 Gly Ile Leu Pro Asp Glu Ala Ser Glu Ala Phe Arg Asn Ser Ser Met 610 615 620 Ala Leu Gln Gln Ala His Leu Leu Lys Asn Met Ser His Cys Arg Gln 625 630 635 640 Pro Ser Asp Ser Ser Val Asp Lys Phe Val Leu Arg Asp Glu Ala Thr 645 650 655 Glu Pro Gly Asp Gln Glu Asn Lys Pro Cys Arg Ile Lys Gly Asp Ile 660 665 670 Gly Gln Ser Thr Asp Asp Asp Ser Ala Pro Leu Val His Cys Val Arg 675 680 685 Leu Leu Ser Ala Ser Phe Leu Leu Thr Gly Gly Lys Asn Val Leu Val 690 695 700 Pro Asp Arg Asp Val Arg Val Ser Val Lys Ala Leu Ala Leu Ser Cys 705 710 715 720 Val Gly Ala Ala Val Ala Leu His Pro Glu Ser Phe Phe Ser Lys Leu 725 730 735 Tyr Lys Val Pro Leu Asp Thr Thr Glu Tyr Pro Glu Glu Gln Tyr Val 740 745 750 Ser Asp Ile Leu Asn Tyr Ile Asp His Gly Asp Pro Gln Val Arg Gly 755 760 765 Ala Thr Ala Ile Leu Cys Gly Thr Leu Ile Cys Ser Ile Leu Ser Arg 770 775 780 Ser Arg Phe His Val Gly Asp Trp Met Gly Thr Ile Arg Thr Leu Thr 785 790 795 800 Gly Asn Thr Phe Ser Leu Ala Asp Cys Ile Pro Leu Leu Arg Lys Thr 805 810 815 Leu Lys Asp Glu Ser Ser Val Thr Cys Lys Leu Ala Cys Thr Ala Val 820 825 830 Arg Asn Cys Val Met Ser Leu Cys Ser Ser Ser Tyr Ser Glu Leu Gly 835 840 845 Leu Gln Leu Ile Ile Asp Val Leu Thr Leu Arg Asn Ser Ser Tyr Trp 850 855 860 Leu Val Arg Thr Glu Leu Leu Glu Thr Leu Ala Glu Ile Asp Phe Arg 865 870 875 880 Leu Val Ser Phe Leu Glu Ala Lys Ala Glu Asn Leu His Arg Gly Ala 885 890 895 His His Tyr Thr Gly Leu Leu Lys Leu Gln Glu Arg Val Leu Asn Asn 900 905 910 Val Val Ile His Leu Leu Gly Asp Glu Asp Pro Arg Val Arg His Val 915 920 925 Ala Ala Ala Ser Leu Ile Arg Leu Val Pro Lys Leu Phe Tyr Lys Cys 930 935 940 Asp Gln Gly Gln Ala Asp Pro Val Val Ala Val Ala Arg Asp Gln Ser 945 950 955 960 Ser Val Tyr Leu Lys Leu Leu Met His Glu Thr Gln Pro Pro Ser His 965 970 975 Phe Ser Val Ser Thr Ile Thr Arg Ile Tyr Arg Gly Tyr Asn Leu Leu 980 985 990 Pro Ser Ile Thr Asp Val Thr Met Glu Asn Asn Leu Ser Arg Val Ile 995 1000 1005 Ala Ala Val Ser His Glu Leu Ile Thr Ser Thr Thr Arg Ala Leu 1010 1015 1020 Thr Phe Gly Cys Cys Glu Ala Leu Cys Leu Leu Ser Thr Ala Phe 1025 1030 1035 Pro Val Cys Ile Trp Ser Leu Gly Trp His Cys Gly Val Pro Pro 1040 1045 1050 Leu Ser Ala Ser Asp Glu Ser Arg Lys Ser Cys Thr Val Gly Met 1055 1060 1065 Ala Thr Met Ile Leu Thr Leu Leu Ser Ser Ala Trp Phe Pro Leu 1070 1075 1080 Asp Leu Ser Ala His Gln Asp Ala Leu Ile Leu Ala Gly Asn Leu 1085 1090 1095 Leu Ala Ala Ser Ala Pro Lys Ser Leu Arg Ser Ser Trp Ala Ser 1100 1105 1110 Glu Glu Glu Ala Asn Pro Ala Ala Thr Lys Gln Glu Glu Val Trp 1115 1120 1125 Pro Ala Leu Gly Asp Arg Ala Leu Val Pro Met Val Glu Gln Leu 1130 1135 1140 Phe Ser His Leu Leu Lys Val Ile Asn Ile Cys Ala His Val Leu 1145 1150 1155 Asp Asp Val Ala Pro Gly Pro Ala Ile Lys Ala Ala Leu Pro Ser 1160 1165 1170 Leu Thr Asn Pro Pro Ser Leu Ser Pro Ile Arg Arg Lys Gly Lys 1175 1180 1185 Glu Lys Glu Pro Gly Glu Gln Ala Ser Val Pro Leu Ser Pro Lys 1190 1195 1200 Lys Gly Ser Glu Ala Ser Ala Ala Ser Arg Gln Ser Asp Thr Ser 1205 1210 1215 Gly Pro Val Thr Thr Ser Lys Ser Ser Ser Leu Gly Ser Phe Tyr 1220 1225 1230 His Leu Pro Ser Tyr Leu Lys Leu His Asp Val Leu Lys Ala Thr 1235 1240 1245 His Ala Asn Tyr Lys Val Thr Leu Asp Leu Gln Asn Ser Thr Glu 1250 1255 1260 Lys Phe Gly Gly Phe Leu Arg Ser Ala Leu Asp Val Leu Ser Gln 1265 1270 1275 Ile Leu Glu Leu Ala Thr Leu Gln Asp Ile Gly Lys Cys Val Glu 1280 1285 1290 Glu Ile Leu Gly Tyr Leu Lys Ser Cys Phe Ser Arg Glu Pro Met 1295 1300 1305 Met Ala Thr Val Cys Val Gln Gln Leu Leu Lys Thr Leu Phe Gly 1310 1315 1320 Thr Asn Leu Ala Ser Gln Phe Asp Gly Leu Ser Ser Asn Pro Ser 1325 1330 1335 Lys Ser Gln Gly Arg Ala Gln Arg Leu Gly Ser Ser Ser Val Arg 1340 1345 1350 Pro Gly Leu Tyr His Tyr Cys Phe Met Ala Pro Tyr Thr His Phe 1355 1360 1365 Thr Gln Ala Leu Ala Asp Ala Ser Leu Arg Asn Met Val Gln Ala 1370 1375 1380 Glu Gln Glu Asn Asp Thr Ser Gly Trp Phe Asp Val Leu Gln Lys 1385 1390 1395 Val Ser Thr Gln Leu Lys Thr Asn Leu Thr Ser Val Thr Lys Asn 1400 1405 1410 Arg Ala Asp Lys Asn Ala Ile His Asn His Ile Arg Leu Phe Glu 1415 1420 1425 Pro Leu Val Ile Lys Ala Leu Lys Gln Tyr Thr Thr Thr Thr Cys 1430 1435 1440 Val Gln Leu Gln Lys Gln Val Leu Asp Leu Leu Ala Gln Leu Val 1445 1450 1455 Gln Leu Arg Val Asn Tyr Cys Leu Leu Asp Ser Asp Gln Val Phe 1460 1465 1470 Ile Gly Phe Val Leu Lys Gln Phe Glu Tyr Ile Glu Val Gly Gln 1475 1480 1485 Phe Arg Glu Ser Glu Ala Ile Ile Pro Asn Ile Phe Phe Phe Leu 1490 1495 1500 Val Leu Leu Ser Tyr Glu Arg Tyr His Ser Lys Gln Ile Ile Gly 1505 1510 1515 Ile Pro Lys Ile Ile Gln Leu Cys Asp Gly Ile Met Ala Ser Gly 1520 1525 1530 Arg Lys Ala Val Thr His Ala Ile Pro Ala Leu Gln Pro Ile Val 1535 1540 1545 His Asp Leu Phe Val Leu Arg Gly Thr Asn Lys Ala Asp Ala Gly 1550 1555 1560 Lys Glu Leu Glu Thr Gln Lys Glu Val Val Val Ser Met Leu Leu 1565 1570 1575 Arg Leu Ile Gln Tyr His Gln Val Leu Glu Met Phe Ile Leu Val 1580 1585 1590 Leu Gln Gln Cys His Lys Glu Asn Glu Asp Lys Trp Lys Arg Leu 1595 1600 1605 Ser Arg Gln Ile Ala Asp Ile Ile Leu Pro Met Leu Ala Lys Gln 1610 1615 1620 Gln Met His Ile Asp Ser His Glu Ala Leu Gly Val Leu Asn Thr 1625 1630 1635 Leu Phe Glu Ile Leu Ala Pro Ser Ser Leu Arg Pro Val Asp Met 1640 1645 1650 Leu Leu Arg Ser Met Phe Val Thr Pro Asn Thr Met Ala Ser Val 1655 1660 1665 Ser Thr Val Gln Leu Trp Ile Ser Gly Ile Leu Ala Ile Leu Arg 1670 1675 1680 Val Leu Ile Ser Gln Ser Thr Glu Asp Ile Val Leu Ser Arg Ile 1685 1690 1695 Gln Glu Leu Ser Phe Ser Pro Tyr Leu Ile Ser Cys Thr Val Ile 1700 1705 1710 Asn Arg Leu Arg Asp Gly Asp Ser Thr Ser Thr Leu Glu Glu His 1715 1720 1725 Ser Glu Gly Lys Gln Ile Lys Asn Leu Pro Glu Glu Thr Phe Ser 1730 1735 1740 Arg Phe Leu Leu Gln Leu Val Gly Ile Leu Leu Glu Asp Ile Val 1745 1750 1755 Thr Lys Gln Leu Lys Val Glu Met Ser Glu Gln Gln His Thr Phe 1760 1765 1770 Tyr Cys Gln Glu Leu Gly Thr Leu Leu Met Cys Leu Ile His Ile 1775 1780 1785 Phe Lys Ser Gly Met Phe Arg Arg Ile Thr Ala Ala Ala Thr Arg 1790 1795 1800 Leu Phe Arg Ser Asp Gly Cys Gly Gly Ser Phe Tyr Thr Leu Asp 1805 1810 1815 Ser Leu Asn Leu Arg Ala Arg Ser Met Ile Thr Thr His Pro Ala 1820 1825 1830 Leu Val Leu Leu Trp Cys Gln Ile Leu Leu Leu Val Asn His Thr 1835 1840 1845 Asp Tyr Arg Trp Trp Ala Glu Val Gln Gln Thr Pro Lys Arg His 1850 1855 1860 Ser Leu Ser Ser Thr Lys Leu Leu Ser Pro Gln Met Ser Gly Glu 1865 1870 1875 Glu Glu Asp Ser Asp Leu Ala Ala Lys Leu Gly Met Cys Asn Arg 1880 1885 1890 Glu Ile Val Arg Arg Gly Ala Leu Ile Leu Phe Cys Asp Tyr Val 1895 1900 1905 Cys Gln Asn Leu His Asp Ser Glu His Leu Thr Trp Leu Ile Val 1910 1915 1920 Asn His Ile Gln Asp Leu Ile Ser Leu Ser His Glu Pro Pro Val 1925 1930 1935 Gln Asp Phe Ile Ser Ala Val His Arg Asn Ser Ala Ala Ser Gly 1940 1945 1950 Leu Phe Ile Gln Ala Ile Gln Ser Arg Cys Glu Asn Leu Ser Thr 1955 1960 1965 Pro Thr Met Leu Lys Lys Thr Leu Gln Cys Leu Glu Gly Ile His 1970 1975 1980 Leu Ser Gln Ser Gly Ala Val Leu Thr Leu Tyr Val Asp Arg Leu 1985 1990 1995 Leu Cys Thr Pro Phe Arg Val Leu Ala Arg Met Val Asp Ile Leu 2000 2005 2010 Ala Cys Arg Arg Val Glu Met Leu Leu Ala Ala Asn Leu Gln Ser 2015 2020 2025 Ser Met Ala Gln Leu Pro Met Glu Glu Leu Asn Arg Ile Gln Glu 2030 2035 2040 Tyr Leu Gln Ser Ser Gly Leu Ala Gln Arg His Gln Arg Leu Tyr 2045 2050 2055 Ser Leu Leu Asp Arg Phe Arg Leu Ser Thr Met Gln Asp Ser Leu 2060 2065 2070 Ser Pro Ser Pro Pro Val Ser Ser His Pro Leu Asp Gly Asp Gly 2075 2080 2085 His Val Ser Leu Glu Thr Val Ser Pro Asp Lys Asp Trp Tyr Val 2090 2095 2100 His Leu Val Lys Ser Gln Cys Trp Thr Arg Ser Asp Ser Ala Leu 2105 2110 2115 Leu Glu Gly Ala Glu Leu Val Asn Arg Ile Pro Ala Glu Asp Met 2120 2125 2130 Asn Ala Phe Met Met Asn Ser Glu Phe Asn Leu Ser Leu Leu Ala 2135 2140 2145 Pro Cys Leu Ser Leu Gly Met Ser Glu Ile Ser Gly Gly Gln Lys 2150 2155 2160 Ser Ala Leu Phe Glu Ala Ala Arg Glu Val Thr Leu Ala Arg Val 2165 2170 2175 Ser Gly Thr Val Gln Gln Leu Pro Ala Val His His Val Phe Gln 2180 2185 2190 Pro Glu Leu Pro Ala Glu Pro Ala Ala Tyr Trp Ser Lys Leu Asn 2195 2200 2205 Asp Leu Phe Gly Asp Ala Ala Leu Tyr Gln Ser Leu Pro Thr Leu 2210 2215 2220 Ala Arg Ala Leu Ala Gln Tyr Leu Val Val Val Ser Lys Leu Pro 2225 2230 2235 Ser His Leu His Leu Pro Pro Glu Lys Glu Lys Asp Ile Val Lys 2240 2245 2250 Phe Val Val Ala Thr Leu Glu Ala Leu Ser Trp His Leu Ile His 2255 2260 2265 Glu Gln Ile Pro Leu Ser Leu Asp Leu Gln Ala Gly Leu Asp Cys 2270 2275 2280 Cys Cys Leu Ala Leu Gln Leu Pro Gly Leu Trp Ser Val Val Ser 2285 2290 2295 Ser Thr Glu Phe Val Thr His Ala Cys Ser Leu Ile Tyr Cys Val 2300 2305 2310 His Phe Ile Leu Glu Ala Val Ala Val Gln Pro Gly Glu Gln Leu 2315 2320 2325 Leu Ser Pro Glu Arg Arg Thr Asn Thr Pro Lys Ala Ile Ser Glu 2330 2335 2340 Glu Glu Glu Glu Val Asp Pro Asn Thr Gln Asn Pro Lys Tyr Ile 2345 2350 2355 Thr Ala Ala Cys Glu Met Val Ala Glu Met Val Glu Ser Leu Gln 2360 2365 2370 Ser Val Leu Ala Leu Gly His Lys Arg Asn Ser Gly Val Pro Ala 2375 2380 2385 Phe Leu Thr Pro Leu Leu Arg Asn Ile Ile Ile Ser Leu Ala Arg 2390 2395 2400 Leu Pro Leu Val Asn Ser Tyr Thr Arg Val Pro Pro Leu Val Trp 2405 2410 2415 Lys Leu Gly Trp Ser Pro Lys Pro Gly Gly Asp Phe Gly Thr Ala 2420 2425 2430 Phe Pro Glu Ile Pro Val Glu Phe Leu Gln Glu Lys Glu Val Phe 2435 2440 2445 Lys Glu Phe Ile Tyr Arg Ile Asn Thr Leu Gly Trp Thr Ser Arg 2450 2455 2460 Thr Gln Phe Glu Glu Thr Trp Ala Thr Leu Leu Gly Val Leu Val 2465 2470 2475 Thr Gln Pro Leu Val Met Glu Gln Glu Glu Ser Pro Pro Glu Glu 2480 2485 2490 Asp Thr Glu Arg Thr Gln Ile Asn Val Leu Ala Val Gln Ala Ile 2495 2500 2505 Thr Ser Leu Val Leu Ser Ala Met Thr Val Pro Val Ala Gly Asn 2510 2515 2520 Pro Ala Val Ser Cys Leu Glu Gln Gln Pro Arg Asn Lys Pro Leu 2525 2530 2535 Lys Ala Leu Asp Thr Arg Phe Gly Arg Lys Leu Ser Ile Ile Arg 2540 2545 2550 Gly Ile Val Glu Gln Glu Ile Gln Ala Met Val Ser Lys Arg Glu 2555 2560 2565 Asn Ile Ala Thr His His Leu Tyr Gln Ala Trp Asp Pro Val Pro 2570 2575 2580 Ser Leu Ser Pro Ala Thr Thr Gly Ala Leu Ile Ser His Glu Lys 2585 ​​2590 2595 Leu Leu Leu Gln Ile Asn Pro Glu Arg Glu Leu Gly Ser Met Ser 2600 2605 2610 Tyr Lys Leu Gly Gln Val Ser Ile His Ser Val Trp Leu Gly Asn 2615 2620 2625 Ser Ile Thr Pro Leu Arg Glu Glu Glu Trp Asp Glu Glu Glu Glu 2630 2635 2640 Glu Glu Ala Asp Ala Pro Ala Pro Ser Ser Pro Pro Thr Ser Pro 2645 2650 2655 Val Asn Ser Arg Lys His Arg Ala Gly Val Asp Ile His Ser Cys 2660 2665 2670 Ser Gln Phe Leu Leu Glu Leu Tyr Ser Arg Trp Ile Leu Pro Ser 2675 2680 2685 Ser Ser Ala Arg Arg Thr Pro Ala Ile Leu Ile Ser Glu Val Val 2690 2695 2700 Arg Ser Leu Leu Val Val Ser Asp Leu Phe Thr Glu Arg Asn Gln 2705 ​​2710 2715 Phe Glu Leu Met Tyr Val Thr Leu Thr Glu Leu Arg Arg Val His 2720 ​​2725 2730 Pro Ser Glu Asp Glu Ile Leu Ala Gln Tyr Leu Val Pro Ala Thr 2735 2740 2745 Cys Lys Ala Ala Ala Val Leu Gly Met Asp Lys Ala Val Ala Glu 2750 2755 2760 Pro Val Ser Arg Leu Leu Glu Ser Thr Leu Arg Ser Ser His Leu 2765 2770 2775 Pro Ser Arg Val Gly Ala Leu His Gly Val Leu Tyr Val Leu Glu 2780 2785 2790 Cys Asp Leu Leu Asp Asp Thr Ala Lys Gln Leu Ile Pro Val Ile 2795 2800 2805 Ser Asp Tyr Leu Leu Ser Asn Leu Lys Gly Ile Ala His Cys Val 2810 2815 2820 Asn Ile His Ser Gln Gln His Val Leu Val Met Cys Ala Thr Ala 2825 2830 2835 Phe Tyr Leu Ile Glu Asn Tyr Pro Leu Asp Val Gly Pro Glu Phe 2840 2845 2850 Ser Ala Ser Ile Ile Gln Met Cys Gly Val Met Leu Ser Gly Ser 2855 2860 2865 Glu Glu Ser Thr Pro Ser Ile Ile Tyr His Cys Ala Leu Arg Gly 2870 2875 2880 Leu Glu Arg Leu Leu Leu Ser Glu Gln Leu Ser Arg Leu Asp Ala 2885 2890 2895 Glu Ser Leu Val Lys Leu Ser Val Asp Arg Val Asn Val His Ser 2900 2905 2910 Pro His Arg Ala Met Ala Ala Leu Gly Leu Met Leu Thr Cys Met 2915 2920 2925 Tyr Thr Gly Lys Glu Lys Val Ser Pro Gly Arg Thr Ser Asp Pro 2930 2935 2940 Asn Pro Ala Ala Pro Asp Ser Glu Ser Val Ile Val Ala Met Glu 2945 2950 2955 Arg Val Ser Val Leu Phe Asp Arg Ile Arg Lys Gly Phe Pro Cys 2960 2965 2970 Glu Ala Arg Val Val Ala Arg Ile Leu Pro Gln Phe Leu Asp Asp 2975 2980 2985 Phe Phe Pro Pro Gln Asp Ile Met Asn Lys Val Ile Gly Glu Phe 2990 2995 3000 Leu Ser Asn Gln Gln Pro Tyr Pro Gln Phe Met Ala Thr Val Val 3005 3010 3015 Tyr Lys Val Phe Gln Thr Leu His Ser Thr Gly Gln Ser Ser Met 3020 3025 3030 Val Arg Asp Trp Val Met Leu Ser Leu Ser Asn Phe Thr Gln Arg 3035 3040 3045 Ala Pro Val Ala Met Ala Thr Trp Ser Leu Ser Cys Phe Phe Val 3050 3055 3060 Ser Ala Ser Thr Ser Pro Trp Val Ala Ala Ile Leu Pro His Val 3065 3070 3075 Ile Ser Arg Met Gly Lys Leu Glu Gln Val Asp Val Asn Leu Phe 3080 3085 3090 Cys Leu Val Ala Thr Asp Phe Tyr Arg His Gln Ile Glu Glu Glu 3095 3100 3105 Leu Asp Arg Arg Ala Phe Gln Ser Val Leu Glu Val Val Ala Ala 3110 3115 3120 Pro Gly Ser Pro Tyr His Arg Leu Leu Thr Cys Leu Arg Asn Val 3125 3130 3135 His Lys Val Thr Thr Cys 3140 <210> 3 <211> 412 <212> PRT <213> Homo sapiens <220> <223> ATXN3-Q74 <400> 3 Met Glu Ser Ile Phe His Glu Lys Gln Glu Gly Ser Leu Cys Ala Gln 1 5 10 15 His Cys Leu Asn Asn Leu Leu Gln Gly Glu Tyr Phe Ser Pro Val Glu 20 25 30 Leu Ser Ser Ile Ala His Gln Leu Asp Glu Glu Glu Arg Met Arg Met 35 40 45 Ala Glu Gly Gly Val Thr Ser Glu Asp Tyr Arg Thr Phe Leu Gln Gln 50 55 60 Pro Ser Gly Asn Met Asp Asp Ser Gly Phe Phe Ser Ile Gln Val Ile 65 70 75 80 Ser Asn Ala Leu Lys Val Trp Gly Leu Glu Leu Ile Leu Phe Asn Ser 85 90 95 Pro Glu Tyr Gln Arg Leu Arg Ile Asp Pro Ile Asn Glu Arg Ser Phe 100 105 110 Ile Cys Asn Tyr Lys Glu His Trp Phe Thr Val Arg Lys Leu Gly Lys 115 120 125 Gln Trp Phe Asn Leu Asn Ser Leu Leu Thr Gly Pro Glu Leu Ile Ser 130 135 140 Asp Thr Tyr Leu Ala Leu Phe Leu Ala Gln Leu Gln Gln Glu Gly Tyr 145 150 155 160 Ser Ile Phe Val Val Lys Gly Asp Leu Pro Asp Cys Glu Ala Asp Gln 165 170 175 Leu Leu Gln Met Ile Arg Val Gln Gln Met His Arg Pro Lys Leu Ile 180 185 190 Gly Glu Glu Leu Ala Gln Leu Lys Glu Gln Arg Val His Lys Thr Asp 195 200 205 Leu Glu Arg Met Leu Glu Ala Asn Asp Gly Ser Gly Met Leu Asp Glu 210 215 220 Asp Glu Glu Asp Leu Gln Arg Ala Leu Ala Leu Ser Arg Gln Glu Ile 225 230 235 240 Asp Met Glu Asp Glu Glu Ala Asp Leu Arg Arg Ala Ile Gln Leu Ser 245 250 255 Met Gln Gly Ser Ser Arg Asn Ile Ser Gln Asp Met Thr Gln Thr Ser 260 265 270 Gly Thr Asn Leu Thr Ser Glu Glu Leu Arg Lys Arg Arg Glu Ala Tyr 275 280 285 Phe Glu Lys Gln Gln Gln Lys Gln Gln Gln Gln Gln Gln Gln Gln Gln 290 295 300 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 305 310 315 320 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 325 330 335 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 340 345 350 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 355 360 365 Gln Arg Asp Leu Ser Gly Gln Ser Ser His Pro Cys Glu Arg Pro Ala 370 375 380 Thr Ser Ser Gly Ala Leu Gly Ser Asp Leu Gly Lys Ala Cys Ser Pro 385 390 395 400 Phe Ile Met Phe Ala Thr Phe Thr Leu Tyr Leu Thr 405 410 <210> 4 <211> 365 <212> PRT <213> Homo sapiens <220> <223> ATXN3-Q27 <400> 4 Met Glu Ser Ile Phe His Glu Lys Gln Glu Gly Ser Leu Cys Ala Gln 1 5 10 15 His Cys Leu Asn Asn Leu Leu Gln Gly Glu Tyr Phe Ser Pro Val Glu 20 25 30 Leu Ser Ser Ile Ala His Gln Leu Asp Glu Glu Glu Arg Met Arg Met 35 40 45 Ala Glu Gly Gly Val Thr Ser Glu Asp Tyr Arg Thr Phe Leu Gln Gln 50 55 60 Pro Ser Gly Asn Met Asp Asp Ser Gly Phe Phe Ser Ile Gln Val Ile 65 70 75 80 Ser Asn Ala Leu Lys Val Trp Gly Leu Glu Leu Ile Leu Phe Asn Ser 85 90 95 Pro Glu Tyr Gln Arg Leu Arg Ile Asp Pro Ile Asn Glu Arg Ser Phe 100 105 110 Ile Cys Asn Tyr Lys Glu His Trp Phe Thr Val Arg Lys Leu Gly Lys 115 120 125 Gln Trp Phe Asn Leu Asn Ser Leu Leu Thr Gly Pro Glu Leu Ile Ser 130 135 140 Asp Thr Tyr Leu Ala Leu Phe Leu Ala Gln Leu Gln Gln Glu Gly Tyr 145 150 155 160 Ser Ile Phe Val Val Lys Gly Asp Leu Pro Asp Cys Glu Ala Asp Gln 165 170 175 Leu Leu Gln Met Ile Arg Val Gln Gln Met His Arg Pro Lys Leu Ile 180 185 190 Gly Glu Glu Leu Ala Gln Leu Lys Glu Gln Arg Val His Lys Thr Asp 195 200 205 Leu Glu Arg Met Leu Glu Ala Asn Asp Gly Ser Gly Met Leu Asp Glu 210 215 220 Asp Glu Glu Asp Leu Gln Arg Ala Leu Ala Leu Ser Arg Gln Glu Ile 225 230 235 240 Asp Met Glu Asp Glu Glu Ala Asp Leu Arg Arg Ala Ile Gln Leu Ser 245 250 255 Met Gln Gly Ser Ser Arg Asn Ile Ser Gln Asp Met Thr Gln Thr Ser 260 265 270 Gly Thr Asn Leu Thr Ser Glu Glu Leu Arg Lys Arg Arg Glu Ala Tyr 275 280 285 Phe Glu Lys Gln Gln Gln Lys Gln Gln Gln Gln Gln Gln Gln Gln Gln 290 295 300 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 305 310 315 320 Gln Gln Arg Asp Leu Ser Gly Gln Ser Ser His Pro Cys Glu Arg Pro 325 330 335 Ala Thr Ser Ser Gly Ala Leu Gly Ser Asp Leu Gly Lys Ala Cys Ser 340 345 350 Pro Phe Ile Met Phe Ala Thr Phe Thr Leu Tyr Leu Thr 355 360 365 <210> 5 <211> 895 <212> PRT <213> Homo sapiens <220> <223> ATXN1-Q92 <400> 5 Met Lys Ser Asn Gln Glu Arg Ser Asn Glu Cys Leu Pro Pro Lys Lys 1 5 10 15 Arg Glu Ile Pro Ala Thr Ser Arg Ser Ser Glu Glu Lys Ala Pro Thr 20 25 30 Leu Pro Ser Asp Asn His Arg Val Glu Gly Thr Ala Trp Leu Pro Gly 35 40 45 Asn Pro Gly Gly Arg Gly His Gly Gly Gly Arg His Gly Pro Ala Gly 50 55 60 Thr Ser Val Glu Leu Gly Leu Gln Gln Gly Ile Gly Leu His Lys Ala 65 70 75 80 Leu Ser Thr Gly Leu Asp Tyr Ser Pro Pro Ser Ala Pro Arg Ser Val 85 90 95 Pro Val Ala Thr Thr Leu Pro Ala Ala Tyr Ala Thr Pro Gln Pro Gly 100 105 110 Thr Pro Val Ser Pro Val Gln Tyr Ala His Leu Pro His Thr Phe Gln 115 120 125 Phe Ile Gly Ser Ser Gln Tyr Ser Gly Thr Tyr Ala Ser Phe Ile Pro 130 135 140 Ser Gln Leu Ile Pro Pro Thr Ala Asn Pro Val Thr Ser Ala Val Ala 145 150 155 160 Ser Ala Ala Gly Ala Thr Thr Pro Ser Gln Arg Ser Gln Leu Glu Ala 165 170 175 Tyr Ser Thr Leu Leu Ala Asn Met Gly Ser Leu Ser Gln Thr Pro Gly 180 185 190 His Lys Ala Glu Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 195 200 205 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 210 215 220 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 225 230 235 240 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 245 250 255 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 260 265 270 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 275 280 285 His Gln His Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 290 295 300 Gln His Leu Ser Arg Ala Pro Gly Leu Ile Thr Pro Gly Ser Pro Pro 305 310 315 320 Pro Ala Gln Gln Asn Gln Tyr Val His Ile Ser Ser Ser Pro Gln Asn 325 330 335 Thr Gly Arg Thr Ala Ser Pro Pro Ala Ile Pro Val His Leu His Pro 340 345 350 His Gln Thr Met Ile Pro His Thr Leu Thr Leu Gly Pro Pro Ser Gln 355 360 365 Val Val Met Gln Tyr Ala Asp Ser Gly Ser His Phe Val Pro Arg Glu 370 375 380 Ala Thr Lys Lys Ala Glu Ser Ser Arg Leu Gln Gln Ala Ile Gln Ala 385 390 395 400 Lys Glu Val Leu Asn Gly Glu Met Glu Lys Ser Arg Arg Tyr Gly Ala 405 410 415 Pro Ser Ser Ala Asp Leu Gly Leu Gly Lys Ala Gly Gly Lys Ser Val 420 425 430 Pro His Pro Tyr Glu Ser Arg His Val Val Val His Pro Ser Pro Ser 435 440 445 Asp Tyr Ser Ser Arg Asp Pro Ser Gly Val Arg Ala Ser Val Met Val 450 455 460 Leu Pro Asn Ser Asn Thr Pro Ala Ala Asp Leu Glu Val Gln Gln Ala 465 470 475 480 Thr His Arg Glu Ala Ser Pro Ser Thr Leu Asn Asp Lys Ser Gly Leu 485 490 495 His Leu Gly Lys Pro Gly His Arg Ser Tyr Ala Leu Ser Pro His Thr 500 505 510 Val Ile Gln Thr Thr His Ser Ala Ser Glu Pro Leu Pro Val Gly Leu 515 520 525 Pro Ala Thr Ala Phe Tyr Ala Gly Thr Gln Pro Pro Val Ile Gly Tyr 530 535 540 Leu Ser Gly Gln Gln Gln Ala Ile Thr Tyr Ala Gly Ser Leu Pro Gln 545 550 555 560 His Leu Val Ile Pro Gly Thr Gln Pro Leu Leu Ile Pro Val Gly Ser 565 570 575 Thr Asp Met Glu Ala Ser Gly Ala Ala Pro Ala Ile Val Thr Ser Ser 580 585 590 Pro Gln Phe Ala Ala Val Pro His Thr Phe Val Thr Thr Ala Leu Pro 595 600 605 Lys Ser Glu Asn Phe Asn Pro Glu Ala Leu Val Thr Gln Ala Ala Tyr 610 615 620 Pro Ala Met Val Gln Ala Gln Ile His Leu Pro Val Val Gln Ser Val 625 630 635 640 Ala Ser Pro Ala Ala Ala Pro Pro Thr Leu Pro Pro Tyr Phe Met Lys 645 650 655 Gly Ser Ile Ile Gln Leu Ala Asn Gly Glu Leu Lys Lys Val Glu Asp 660 665 670 Leu Lys Thr Glu Asp Phe Ile Gln Ser Ala Glu Ile Ser Asn Asp Leu 675 680 685 Lys Ile Asp Ser Ser Thr Val Glu Arg Ile Glu Asp Ser His Ser Pro 690 695 700 Gly Val Ala Val Ile Gln Phe Ala Val Gly Glu His Arg Ala Gln Val 705 710 715 720 Ser Val Glu Val Leu Val Glu Tyr Pro Phe Phe Val Phe Gly Gln Gly 725 730 735 Trp Ser Ser Cys Cys Pro Glu Arg Thr Ser Gln Leu Phe Asp Leu Pro 740 745 750 Cys Ser Lys Leu Ser Val Gly Asp Val Cys Ile Ser Leu Thr Leu Lys 755 760 765 Asn Leu Lys Asn Gly Ser Val Lys Lys Gly Gln Pro Val Asp Pro Ala 770 775 780 Ser Val Leu Leu Lys His Ser Lys Ala Asp Gly Leu Ala Gly Ser Arg 785 790 795 800 His Arg Tyr Ala Glu Gln Glu Asn Gly Ile Asn Gln Gly Ser Ala Gln 805 810 815 Met Leu Ser Glu Asn Gly Glu Leu Lys Phe Pro Glu Lys Met Gly Leu 820 825 830 Pro Ala Ala Pro Phe Leu Thr Lys Ile Glu Pro Ser Lys Pro Ala Ala 835 840 845 Thr Arg Lys Arg Arg Trp Ser Ala Pro Glu Ser Arg Lys Leu Glu Lys 850 855 860 Ser Glu Asp Glu Pro Pro Leu Thr Leu Pro Lys Pro Ser Leu Ile Pro 865 870 875 880 Gln Glu Val Lys Ile Cys Ile Glu Gly Arg Ser Asn Val Gly Lys 885 890 895

Claims

1. Use of a compound or a pharmaceutically acceptable salt or stereoisomer thereof in the preparation of a medicament for preventing or treating polyQ-related neurodegenerative diseases, wherein The polyQ-related neurodegenerative disease is selected from spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 7, spinocerebellar ataxia type 12, spinocerebellar ataxia type 17, dentate-nigro-rubral-pallido-subthalamic atrophy, Huntington's disease and spinobulbar muscular atrophy; And, wherein the compound is selected from:

2. The method of claim 1, wherein The polyQ-related neurodegenerative disease is spinocerebellar ataxia type 3.

3. Use of the pharmaceutical composition in the preparation of a medicament for preventing or treating PolyQ-related neurodegenerative diseases; wherein The polyQ-related neurodegenerative disease is selected from spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 7, spinocerebellar ataxia type 12, spinocerebellar ataxia type 17, dentate-nigro-rubral-pallido-subthalamic atrophy, Huntington's disease and spinobulbar muscular atrophy; and The pharmaceutical composition comprises the compound defined in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, and at least one pharmaceutically acceptable carrier.

4. Use of a compound or a pharmaceutically acceptable salt or stereoisomer thereof in the preparation of a medicament for preventing or treating Huntington's disease, wherein the compound is selected from:

5. Use of the pharmaceutical composition in the preparation of a medicament for preventing or treating Huntington's disease; wherein The pharmaceutical composition comprises the compound defined in claim 4, or a pharmaceutically acceptable salt or stereoisomer thereof, and at least one pharmaceutically acceptable carrier.

6. Use of a compound or a pharmaceutically acceptable salt or stereoisomer thereof in the preparation of a medicament for preventing or treating spinocerebellar ataxia type 1, wherein the compound is selected from:

7. Use of the pharmaceutical composition in the preparation of a medicament for preventing or treating spinocerebellar ataxia type 1; wherein The pharmaceutical composition comprises the compound defined in claim 6, or a pharmaceutically acceptable salt or stereoisomer thereof, and at least one pharmaceutically acceptable carrier.